

CURRICULUM VITAE

Date of Revision: July 19, 2021
Name: Eric Velazquez, MD
School: Yale School of Medicine

Education:

BA, Williams College Psychology 1988
MD, Albert Einstein College of Medicine 1997

Career/Academic Appointments:

Intern, Department of Medicine, Duke University School of Medicine, Durham, NC
Junior Assistant Resident, Department of Medicine, Duke University School of Medicine, Durham, NC
Visiting Junior Registrar, John Radcliffe Hospital, Oxford, England
Senior Assistant Resident, Department of Medicine, Duke University School of Medicine,, Durham, NC
Fellow, Duke Cardiovascular Disease Fellowship Program, Department of Medicine, Duke University School of Medicine, Durham, NC
Fellow, Advanced Training in Cardiology Fellowship Program, Department of Medicine, Duke University School of Medicine, Durham, NC
Research Fellow, Echocardiography Laboratory, Department of Medicine, Duke University School of Medicine, Durham, NC
Clinical Research Fellow, Duke Clinical Research Institute, Durham, NC
2007 - 2010 Associate Professor of Medicine, Department of Medicine, Duke University School of Medicine,, Durham, NC
2010 - 2012 Associate Professor of Medicine with Tenure, Department of Medicine, Duke University School of Medicine, Durham, NC
2012 - 2018 Professor of Medicine with Tenure, Department of Medicine, Duke University School of Medicine, Durham, NC
2012 - 2018 Professor of Medicine with Tenure, Duke Clinical Research Institute, Duke University, Durham, NC
2018 New Recruit, Cardiology (Medicine), Yale School of Medicine, New Haven, CT
2018 - present Professor, Cardiology (Medicine), Yale School of Medicine, New Haven, CT
2018 - present Robert W. Berliner, Professor, Cardiology (Medicine), Yale School of Medicine, New Haven, CT

Administrative Positions:

2002 - 2006 Director, Heart Failure Research, Department of Medicine, Duke University School of Medicine, Durham, NC

2006 - 2012	Director, Late Phase Cardiovascular Trials, Duke Clinical Research Institute, Duke University, Durham, NC
2007 - 2018	Director, Cardiac Diagnostic Unit and Echocardiography Laboratories, Department of Medicine, Duke University School of Medicine, Durham, NC
2009 - 2018	Chief, Cardiovascular Imaging, Division of Cardiology, Duke University School of Medicine, Durham, NC
2009 - 2018	Associate Director, Duke Heart Center, Duke University School of Medicine, Durham, NC
2012 - 2018	Assistant Director, Clinical Trials, Duke University, Durham, NC
2018 - present	Chief, Cardiovascular Medicine, Yale School of Medicine, New Haven, CT
2018 - present	Chief, Cardiovascular Medicine, Yale New Haven Hospital, Yale New Haven Hospital, New Haven, CT
2018 - present	Physician-in-Chief, Heart and Vascular Center, Yale New Haven Health, Yale New Haven Health, New Haven, CT
2019 - present	Deputy Director, Clinical Trials Innovation, Yale Center for Clinical Investigation (YCCI), Yale School of Medicine, New Haven, CT
2019 - present	Co-Chair, Clinical and Translational Research Oversight Committee, Yale School of Medicine, New Haven, CT
2019 - present	President's contingency planning committee, Clinical Practice/Clinical Research Subcommittee, Yale University, New Haven, CT

Professional Honors & Recognition:

International/National/Regional

2015	Duke University Schools of Medicine and Nursing, Distinguished Nominee, Research Mentor Award
2014	Inducted into the American Society for Clinical Investigation
2014	Who's Who in America
2004	Joseph G. Greenfield, Jr. Faculty Award for Research Mentoring, Nominee
2001	Greenfield Scholar in Cardiology Award
2001	Eugene A. Stead, Jr. Faculty Award for Excellence in Teaching, Nominee
1988	Sigma Xi Honor Society
1988	Williams College, Class of 1960 Scholar
1984	Regis High School, New York, NY, Rogers Award

Grants/Clinical Trials History:

Current Grants

Agency:	TRANSFORM-HF CCC
I.D.#:	5U01HL125511-03
Title:	NIH/NHLBI
P.I.:	ev263
Role:	PI
Percent effort:	N/A

Direct costs per year: N/A
Total costs for project period: \$1,222,610.00
Project period: 8/15/2017 - 7/31/2022

Agency: NIH
I.D.#: 1R01-HL125511-01A1
Title: TRANSFORM-HF CCC
P.I.: Eric J. Velazquez, M.D.
Role: Principal Investigator
Percent effort: 25%
Direct costs per year: \$7,833,484.00
Total costs for project period: \$1,566,696.80
Project period: 4/1/2017 - 7/31/2022

Current Clinical Trials

Agency: NO FUNDING
I.D.#: HIC# 2000028142
Title: Continuous non-invasive hemodynamic monitoring in early-onset severe preeclampsia: a comparison of echocardiography, bioactance, and finger cuff measurements.
P.I.: Josephine C. Chou
Role: Sub-Investigator
Percent effort: N/A
Total costs for project period: N/A
Project period: 6/8/2020

Agency: National Heart, Lung, and Blood Institute (NHLBI)
I.D.#: HIC# 2000023358
Title: TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure
P.I.: Jeffrey Testani
Role: Sub-Investigator
Percent effort: N/A
Total costs for project period: N/A
Project period: 6/8/2018

Past Grants

Agency: Novartis Pharmaceuticals Corp.
I.D.#: NOVA-32

Title: PIONEER-HF Trial
Role: Principal Investigator
Percent effort: 11%
Direct costs per year: \$2,498,967.00
Total costs for project period: \$624,741.75
Project period: 12/14/2015 - 5/31/2019

Past Clinical Trials

Agency: Duke University
I.D.#: HIC# 2000025578NHSR
Title: Surgical Treatment for Ischemic Heart Failure Extended Study
Role: Principal Investigator
Percent effort: N/A
Total costs for project period: N/A
Project period: 5/28/2019 - 5/28/2019

Agency: Duke Clinical Research Institute
I.D.#: HIC# 2000023845
Title: Surgical Treatment for Ischemic Heart (STICH) Failure Trial
Role: Principal Investigator
Percent effort: N/A
Total costs for project period: N/A
Project period: 9/25/2017 - 5/8/2019

Pending Clinical Trials

Agency: Food and Drug Administration (FDA)
I.D.#: HIC# 2000029850EXEMPT
Title: Leveraging Community Engagement and Electronic Health Record strategies to Promote Diverse Participation in COVID-19 Clinical Trials
P.I.: Brian Smith
Role: Sub-Investigator
Percent effort: N/A
Total costs for project period: N/A
Project period: 1/22/2021

Agency: NO FUNDING
I.D.#: HIC# 2000027975REG
Title: Computational Health Platform (CHP) Data Repository
P.I.: Wade Schulz

Role: Sub-Investigator
 Percent effort: N/A
 Total costs for project period: N/A
 Project period: 6/15/2020

Agency: National Heart, Lung, and Blood Institute (NHLBI)
 I.D.#: HIC# 2000023963
 Title: Torsemide Comparison with Furosemide for Management of Heart Failure (TRANSFORM-HF)

Role: Principal Investigator
 Percent effort: N/A
 Total costs for project period: N/A
 Project period: 9/26/2018

Agency: Duke Clinical Research Institute
 I.D.#: HIC# 2000023844
 Title: A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF) (PIONEER-HF)

Role: Principal Investigator
 Percent effort: N/A
 Total costs for project period: N/A
 Project period: 2/20/2018

Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:

International/National

- 2020: The Aga Khan University, Karachi, Sindh, Pakistan. "Pulse-Keynote Speaker"
- 2019: Novartis Innovative Medicines Cardiovascular and Metabolism, São Paulo, SP, Brazil. "Therapy with Sacubitril-Valsartan Should Begin In-Hospital"
- 2019: La Fundacion Santa Fe, Bogota, Bogota, Colombia. "Yale-Fundacion Santa Fe Cardiology Symposium"
- 2019: Korean Society of Cardiology, Busan, Busan, South Korea. "Novartis/ South Korea Symposium"
- 2017: The Egyptian Society of Cardiology, Cairo, Cairo Governorate, Egypt. "The Egyptian Society of Cardiology 44th Annual Congress "CardioEgypt 2017," Cairo, Egypt. Chair for "Myocarditis:"

Regional

2020: NYU School of Medicine/ Langone Medical Center, New York, NY. "Acute Heart Failure Management 2020: Are we on the right path?"

2020: Mount Sinai, New York, NY. "Acute Heart Failure Management 2020: Are we on the right path?"

Bibliography:

Peer-Reviewed Original Research

1. Solomon PR, Blanchard S, Levine E, **Velazquez E**, Groccia-Ellison M. Attenuation of age-related conditioning deficits in humans by extension of the interstimulus interval. *Psychology And Aging* 1991, 6:36-42.
2. Manova K, Bachvarova RF, Huang EJ, Sanchez S, Pronovost SM, **Velazquez E**, McGuire B, Besmer P. c-kit receptor and ligand expression in postnatal development of the mouse cerebellum suggests a function for c-kit in inhibitory interneurons. *The Journal Of Neuroscience : The Official Journal Of The Society For Neuroscience* 1992, 12:4663-76.
3. Solomon PR, Barth CL, Wood MS, **Velazquez E**, Groccia-Ellison M, Yang BY. Age-related deficits in retention of the classically conditioned nictitating membrane response in rabbits. *Behavioral Neuroscience* 1995, 109:18-23.
4. Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, **Velazquez E**, Califf R. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. *American Heart Journal* 2000, 140:727-50.
5. McGuire DK, O'shea JC, Dyke CK, **Velazquez EJ**, Hudson MP. Highlights from the XXII congress of the European Society of Cardiology: August 26 to 30, 2000. *American Heart Journal* 2001, 141:164-72.
6. Shah BR, **Velazquez E**, Shaw LK, Bart B, O'Connor C, Wagner GS. Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-medium myocardial infarcts. *American Heart Journal* 2002, 143:111-7.
7. O'Connor CM, **Velazquez EJ**, Gardner LH, Smith PK, Newman MF, Landolfo KP, Lee KL, Califf RM, Jones RH. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). *The American Journal Of Cardiology* 2002, 90:101-7.
8. Bourque JM, Hasselblad V, **Velazquez EJ**, Borges-Neto S, O'connor CM. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. *American Heart Journal* 2003, 146:621-7.
9. Bourque JM, **Velazquez EJ**, Borges-Neto S, Shaw LK, Whellan DJ, O'Connor CM. Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? *American Heart Journal* 2003, 145:758-67.
10. **Velazquez EJ**, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau JL, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. *European Journal Of Heart Failure* 2003, 5:537-44.
11. Cohn JN, **Velazquez EJ**, Musher J. Symposium reporter 2003. New therapeutic options in the management of hypertension to heart failure. Orlando, Florida, USA, March 6, 2003. *Journal Of The American Medical Directors Association* 2003, 1-16, quiz 17.

12. Pfeffer MA, McMurray JJ, **Velazquez EJ**, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *The New England Journal Of Medicine* 2003, 349:1893-906.
13. Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, **Velazquez EJ**, Weber MA. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. *American Journal Of Hypertension* 2004, 17:793-801.
14. Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, **Velazquez EJ**, Califf RM, Pfeffer MA. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial infarction (VALIANT) trial. *Circulation* 2004, 110:1572-8.
15. Anavekar NS, McMurray JJ, **Velazquez EJ**, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *The New England Journal Of Medicine* 2004, 351:1285-95.
16. Bourque JM, **Velazquez EJ**, Borges-Neto S, Shaw LK, Whellan DJ, O'connor CM. Clinical characteristics and referral pattern of patients with left ventricular dysfunction and significant coronary artery disease undergoing radionuclide imaging. *Journal Of Nuclear Cardiology : Official Publication Of The American Society Of Nuclear Cardiology* 2004, 11:118-25.
17. Liao L, Cabell CH, Jollis JG, **Velazquez EJ**, Smith WT, Anstrom KJ, Pappas PA, Ryan T, Kisslo JA, Landolfo CK. Usefulness of myocardial viability or ischemia in predicting long-term survival for patients with severe left ventricular dysfunction undergoing revascularization. *The American Journal Of Cardiology* 2004, 93:1275-9.
18. **Velazquez EJ**, Francis GS, Armstrong PW, Aylward PE, Diaz R, O'Connor CM, White HD, Henis M, Rittenhouse LM, Kilaru R, van Gilst W, Ertl G, Maggioni AP, Spac J, Weaver WD, Rouleau JL, McMurray JJ, Pfeffer MA, Califf RM. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. *European Heart Journal* 2004, 25:1911-9.
19. Cabell CH, Trichon BH, **Velazquez EJ**, Dumesnil JG, Anstrom KJ, Ryan T, Miller AB, Belkin RN, Cropp AB, O'Connor CM, Jollis JG. Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study. *American Heart Journal* 2004, 147:151-7.
20. Reed SD, Friedman JY, **Velazquez EJ**, Gnanasakthy A, Califf RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). *American Heart Journal* 2004, 148:122-8.
21. **Velazquez EJ**, Pfeffer MA. Acute heart failure complicating acute coronary syndromes: a deadly intersection. *Circulation* 2004, 109:440-2.
22. Crawford TC, Smith WT, **Velazquez EJ**, Taylor SM, Jollis JG, Kisslo J. Prognostic usefulness of left ventricular thrombus by echocardiography in dilated cardiomyopathy in predicting stroke, transient ischemic attack, and death. *The American Journal Of Cardiology* 2004, 93:500-3.

23. Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, **Velazquez EJ**, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). *American Heart Journal* 2005, 150:323-9.
24. Thomas KL, East MA, **Velazquez EJ**, Tuttle RH, Shaw LK, O'Connor CM, Peterson ED. Outcomes by race and etiology of patients with left ventricular systolic dysfunction. *The American Journal Of Cardiology* 2005, 96:956-63.
25. Hernandez AF, **Velazquez EJ**, Solomon SD, Kilaru R, Diaz R, O'Connor CM, Ertl G, Maggioni AP, Rouleau JL, van Gilst W, Pfeffer MA, Califf RM. Left ventricular assessment in myocardial infarction: the VALIANT registry. *Archives Of Internal Medicine* 2005, 165:2162-9.
26. Thomas KL, **Velazquez EJ**. Therapies to prevent heart failure post-myocardial infarction. *Current Heart Failure Reports* 2005, 2:174-82.
27. Benjamin EJ, Jessup M, Flack JM, Krumholz HM, Liu K, Nadkarni VM, Rhoades DA, Rodriguez BL, Scott RP, Taylor MP, **Velazquez EJ**, Winkleby MA. Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Outcomes Writing Group. *Circulation* 2005, 111:e124-33.
28. Doenst T, **Velazquez EJ**, Beyersdorf F, Michler R, Menicanti L, Di Donato M, Gradinac S, Sun B, Rao V. To STICH or not to STICH: we know the answer, but do we understand the question? *The Journal Of Thoracic And Cardiovascular Surgery* 2005, 129:246-9.
29. Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, **Velazquez EJ**, Califf RM, McMurray JV, Pfeffer MA. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. *Circulation* 2005, 111:3411-9.
30. Szummer KE, Solomon SD, **Velazquez EJ**, Kilaru R, McMurray J, Rouleau JL, Mahaffey KW, Maggioni AP, Califf RM, Pfeffer MA, White HD. Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. *European Heart Journal* 2005, 26:2114-9.
31. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, **Velazquez E**, Ertl G, Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, Van de Werf F, Pieper K, Califf RM, Pfeffer MA. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. *The New England Journal Of Medicine* 2005, 352:2581-8.
32. Gheorghide M, Sopko G, De Luca L, **Velazquez EJ**, Parker JD, Binkley PF, Sadowski Z, Golba KS, Prior DL, Rouleau JL, Bonow RO. Navigating the crossroads of coronary artery disease and heart failure. *Circulation* 2006, 114:1202-13.
33. Liu PP, Maggioni A, **Velazquez EJ**. Use of valsartan in post-myocardial infarction and heart failure patients. *Journal Of The Renin-angiotensin-aldosterone System : JRAAS* 2006, 7 Suppl 1:S19-22.
34. Kauf TL, **Velazquez EJ**, Crosslin DR, Weaver WD, Diaz R, Granger CB, McMurray JJ, Rouleau JL, Aylward PE, White HD, Califf RM, Schulman KA. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. *American Heart Journal* 2006, 151:206-12.
35. McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, **Velazquez E**, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). *Journal Of The American College Of Cardiology* 2006, 47:726-33.

36. Yerra L, Anavekar N, Skali H, Zelenkofske S, **Velazquez E**, McMurray J, Pfeffer M, Solomon SD. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. *Heart Rhythm : The Official Journal Of The Heart Rhythm Society* 2006, 3:313-6.
37. Køber L, Swedberg K, McMurray JJ, Pfeffer MA, **Velazquez EJ**, Diaz R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau JL, Leimberger JD, Califf RM. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. *European Journal Of Heart Failure* 2006, 8:591-8.
38. Thune JJ, Køber L, Pfeffer MA, Skali H, Anavekar NS, Bourgoun M, Ghali JK, Arnold JM, **Velazquez EJ**, Solomon SD. Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study. *Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography* 2006, 19:1462-5.
39. Janardhanan R, Kenchaiah S, **Velazquez EJ**, Park Y, McMurray JJ, Weaver WD, Finn PV, White HD, Marin-Neto JA, O'Connor C, Pfeffer MA, Califf RM, Solomon SD. Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *American Heart Journal* 2006, 152:183-9.
40. Whellan DJ, Tuttle RH, **Velazquez EJ**, Shaw LK, Jollis JG, Ellis W, O'Connor CM, Califf RM, Borges-Neto S. Predicting significant coronary artery disease in patients with left ventricular dysfunction. *American Heart Journal* 2006, 152:340-7.
41. Bourque JM, O'Connor CM, **Velazquez EJ**. Letter by Bourque et al regarding article, "Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994". *Circulation* 2006, 114:e255.
42. Hernandez AF, **Velazquez EJ**, Dullum MK, O'Brien SM, Ferguson TB, Peterson ED. Contemporary performance of surgical ventricular restoration procedures: data from the Society of Thoracic Surgeons' National Cardiac Database. *American Heart Journal* 2006, 152:494-9.
43. Reed SD, McMurray JJ, **Velazquez EJ**, Schulman KA, Califf RM, Kober L, Maggioni AP, Van de Werf F, White HD, Diaz R, Mareev V, Murin J. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. *American Heart Journal* 2006, 152:500-8.
44. Weir RA, McMurray JJ, **Velazquez EJ**. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. *The American Journal Of Cardiology* 2006, 97:13F-25F.
45. Weber MA, Bakris GL, Dahlöf B, Pitt B, **Velazquez E**, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. *Blood Pressure* 2007, 16:13-9.
46. Jamerson K, Bakris GL, Dahlöf B, Pitt B, **Velazquez E**, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, Weber M. Exceptional early blood pressure control rates: the ACCOMPLISH trial. *Blood Pressure* 2007, 16:80-6.
47. Amigoni M, Meris A, Thune JJ, Mangalat D, Skali H, Bourgoun M, Warnica JW, Barvik S, Arnold JM, **Velazquez EJ**, Van de Werf F, Ghali J, McMurray JJ, Køber L, Pfeffer MA, Solomon SD. Mitral

- regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. *European Heart Journal* 2007, 28:326-33.
48. Echols MR, Mahaffey KW, Banerjee A, Pieper KS, Stebbins A, Lansky A, Cohen MG, **Velazquez E**, Santos R, Newby LK, Gurfinkel EP, Biasucci L, Ferguson JJ, Califf RM. Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial). *The American Journal Of Cardiology* 2007, 99:315-21.
 49. Stephenson K, Skali H, McMurray JJ, **Velazquez EJ**, Aylward PG, Kober L, Van de Werf F, White HD, Pieper KS, Califf RM, Solomon SD, Pfeffer MA. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. *Heart Rhythm : The Official Journal Of The Heart Rhythm Society* 2007, 4:308-13.
 50. Bourque JM, **Velazquez EJ**, Tuttle RH, Shaw LK, O'Connor CM, Borges-Neto S. Mortality risk associated with ejection fraction differs across resting nuclear perfusion findings. *Journal Of Nuclear Cardiology : Official Publication Of The American Society Of Nuclear Cardiology* 2007, 14:165-73.
 51. Thomas KL, Al-Khatib SM, Kelsey RC, Bush H, Brosius L, **Velazquez EJ**, Peterson ED, Gilliam FR. Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of $\leq 35\%$. *The American Journal Of Cardiology* 2007, 100:924-9.
 52. Verma A, Anavekar NS, Meris A, Thune JJ, Arnold JM, Ghali JK, **Velazquez EJ**, McMurray JJ, Pfeffer MA, Solomon SD. The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. *Journal Of The American College Of Cardiology* 2007, 50:1238-45.
 53. **Velazquez EJ**, Lee KL, O'Connor CM, Oh JK, Bonow RO, Pohost GM, Feldman AM, Mark DB, Panza JA, Sopko G, Rouleau JL, Jones RH. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. *The Journal Of Thoracic And Cardiovascular Surgery* 2007, 134:1540-7.
 54. Tang Z, Diamond MA, Chen JM, Holly TA, Bonow RO, Dasgupta A, Hyslop T, Purzycki A, Wagner J, McNamara DM, Kukulski T, Wos S, **Velazquez EJ**, Ardlie K, Feldman AM. Polymorphisms in adenosine receptor genes are associated with infarct size in patients with ischemic cardiomyopathy. *Clinical Pharmacology And Therapeutics* 2007, 82:435-40.
 55. Prisant LM, Thomas KL, Lewis EF, Huang Z, Francis GS, Weaver WD, Pfeffer MA, McMurray JJ, Califf RM, **Velazquez EJ**. Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. *Journal Of The American College Of Cardiology* 2008, 51:1865-71.
 56. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, **Velazquez EJ**, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. *Blood Pressure* 2008, 17:7-17.
 57. Weinsaft JW, Kim HW, Shah DJ, Klem I, Crowley AL, Brosnan R, James OG, Patel MR, Heitner J, Parker M, **Velazquez EJ**, Steenbergen C, Judd RM, Kim RJ. Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction. *Journal Of The American College Of Cardiology* 2008, 52:148-57.

58. Trimble MA, Borges-Neto S, **Velazquez EJ**, Chen J, Shaw LK, Pagnanelli R, Garcia EV, Iskandrian AE. Emerging role of myocardial perfusion imaging to evaluate patients for cardiac resynchronization therapy. *The American Journal Of Cardiology* 2008, 102:211-7.
59. Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, **Velazquez EJ**, McMurray JJ, Kober L, Pfeffer MA, Califf RM, Solomon SD. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. *JACC. Cardiovascular Imaging* 2008, 1:582-91.
60. Chen J, Garcia EV, Lerakis S, Henneman MM, Bax JJ, Trimble MA, Borges-Neto S, **Velazquez EJ**, Iskandrian AE. Left ventricular mechanical dyssynchrony as assessed by phase analysis of ECG-gated SPECT myocardial perfusion imaging. *Echocardiography (Mount Kisco, N.Y.)* 2008, 25:1186-94.
61. Allen LA, Metra M, Milo-Cotter O, Filippatos G, Reisin LH, Bensimhon DR, Gronda EG, Colombo P, Felker GM, Cas LD, Kremastinos DT, O'Connor CM, Cotter G, Davison BA, Dittrich HC, **Velazquez EJ**. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). *Journal Of Cardiac Failure* 2008, 14:777-84.
62. Piccini JP, Hranitzky PM, Kilaru R, Rouleau JL, White HD, Aylward PE, Van de Werf F, Solomon SD, Califf RM, **Velazquez EJ**. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). *The American Journal Of Cardiology* 2008, 102:1427-32.
63. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, **Velazquez EJ**. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *The New England Journal Of Medicine* 2008, 359:2417-28.
64. Anavekar NS, Skali H, Bourgoun M, Ghali JK, Kober L, Maggioni AP, McMurray JJ, **Velazquez E**, Califf R, Pfeffer MA, Solomon SD. Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). *The American Journal Of Cardiology* 2008, 101:607-12.
65. Lewis EF, **Velazquez EJ**, Solomon SD, Hellkamp AS, McMurray JJ, Mathias J, Rouleau JL, Maggioni AP, Swedberg K, Kober L, White H, Dalby AJ, Francis GS, Zannad F, Califf RM, Pfeffer MA. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. *European Heart Journal* 2008, 29:748-56.
66. Trimble MA, **Velazquez EJ**, Adams GL, Honeycutt EF, Pagnanelli RA, Barnhart HX, Chen J, Iskandrian AE, Garcia EV, Borges-Neto S. Repeatability and reproducibility of phase analysis of gated single-photon emission computed tomography myocardial perfusion imaging used to quantify cardiac dyssynchrony. *Nuclear Medicine Communications* 2008, 29:374-81.
67. Thune JJ, Signorovitch J, Kober L, **Velazquez EJ**, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. *Hypertension* 2008, 51:48-54.
68. Thomas KL, Al-Khatib SM, Lokhnygina Y, Solomon SD, Kober L, McMurray JJ, Califf RM, **Velazquez EJ**. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left

- ventricular dysfunction may be associated with excess mortality. *American Heart Journal* 2008, 155:87-93.
69. Trimble MA, Borges-Neto S, Honeycutt EF, Shaw LK, Pagnanelli R, Chen J, Iskandrian AE, Garcia EV, **Velazquez EJ**. Evaluation of mechanical dyssynchrony and myocardial perfusion using phase analysis of gated SPECT imaging in patients with left ventricular dysfunction. *Journal Of Nuclear Cardiology : Official Publication Of The American Society Of Nuclear Cardiology* 2008, 15:663-70.
 70. Anavekar NS, Solomon SD, McMurray JJ, Maggioni A, Rouleau JL, Califf R, White H, Kober L, **Velazquez E**, Pfeffer MA. Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. *The American Journal Of Cardiology* 2008, 101:925-9.
 71. Anderson RE, Pfeffer MA, Thune JJ, McMurray JJ, Califf RM, **Velazquez E**, White HD, Rouleau JL, Skali H, Maggioni A, Solomon SD. High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarctiOn (VALIANT) trial. *American Heart Journal* 2008, 155:706-11.
 72. Chen J, Garcia EV, Henneman MM, Bax JJ, Boogers MJ, Trimble MA, Borges-Neto S, **Velazquez EJ**, Iskandrian AE. Measuring left ventricular mechanical dyssynchrony from ECG-gated SPECT myocardial perfusion imaging. *Minerva Cardioangiologica* 2008, 56:227-35.
 73. Moukarbel GV, Signorovitch JE, Pfeffer MA, McMurray JJ, White HD, Maggioni AP, **Velazquez EJ**, Califf RM, Scheiman JM, Solomon SD. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. *European Heart Journal* 2009, 30:2226-32.
 74. Califf RM, Lokhnygina Y, **Velazquez EJ**, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). *The American Journal Of Cardiology* 2009, 104:151-7.
 75. Atchley AE, Trimble MA, Samad Z, Shaw LK, Pagnanelli R, Chen J, Garcia EV, Iskandrian AE, **Velazquez EJ**, Borges-Neto S. Use of phase analysis of gated SPECT perfusion imaging to quantify dyssynchrony in patients with mild-to-moderate left ventricular dysfunction. *Journal Of Nuclear Cardiology : Official Publication Of The American Society Of Nuclear Cardiology* 2009, 16:888-94.
 76. Atwater BD, Thompson VP, Vest RN, Shaw LK, Mazzei WR, Al-Khatib SM, Hranitzky PM, Bahnson TD, **Velazquez EJ**, Califf RM, Lee KL, Roe MT. Usefulness of the Duke Sudden Cardiac Death risk score for predicting sudden cardiac death in patients with angiographic (>75% narrowing) coronary artery disease. *The American Journal Of Cardiology* 2009, 104:1624-30.
 77. Jones RH, **Velazquez EJ**, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL. Coronary bypass surgery with or without surgical ventricular reconstruction. *The New England Journal Of Medicine* 2009, 360:1705-17.
 78. Berry C, Pieper KS, White HD, Solomon SD, Van de Werf F, **Velazquez EJ**, Maggioni AP, Califf RM, Pfeffer MA, McMurray JJ. Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarctiOn trial (VALIANT). *European Heart Journal* 2009, 30:1450-6.
 79. Mark DB, Knight JD, **Velazquez EJ**, Howlett JG, Spertus JA, Djokovic LT, Harding TM, Rankin GR, Drew LA, Szygula-Jurkiewicz B, Adlbrecht C, Anstrom KJ. Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial. *American Heart Journal* 2009, 157:837-44, 844.e1-3.
 80. Meris A, Amigoni M, Uno H, Thune JJ, Verma A, Køber L, Bourgoun M, McMurray JJ, **Velazquez EJ**, Maggioni AP, Ghali J, Arnold JM, Zelenkofske S, Pfeffer MA, Solomon SD. Left atrial remodelling in

- patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study. *European Heart Journal* 2009, 30:56-65.
81. Wallace TW, Berger JS, Wang A, **Velazquez EJ**, Brown DL. Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention. *The American Journal Of Cardiology* 2009, 103:355-60.
 82. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, **Velazquez EJ**, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). *European Journal Of Heart Failure* 2009, 11:292-8.
 83. Shah AM, Uno H, Køber L, **Velazquez EJ**, Maggioni AP, MacDonald MR, Petrie MC, McMurray JJ, Califf RM, Pfeffer MA, Solomon SD. The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. *European Journal Of Heart Failure* 2010, 12:1229-37.
 84. Hung CL, Verma A, Uno H, Shin SH, Bourgoun M, Hassanein AH, McMurray JJ, **Velazquez EJ**, Kober L, Pfeffer MA, Solomon SD. Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. *Journal Of The American College Of Cardiology* 2010, 56:1812-22.
 85. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, **Velazquez EJ**, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. *Lancet* 2010, 375:1173-81.
 86. Shin SH, Hung CL, Uno H, Hassanein AH, Verma A, Bourgoun M, Køber L, Ghali JK, **Velazquez EJ**, Califf RM, Pfeffer MA, Solomon SD. Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both. *Circulation* 2010, 121:1096-103.
 87. Gupta M, Honos GN, **Velazquez EJ**, Chung N, Oigman W, Maggioni AP. Evidence for the efficacy of ARBs across the cardiovascular continuum. *Current Medical Research And Opinion* 2010, 26:1203-18.
 88. Nilsson KR, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, **Velazquez EJ**. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. *Heart (British Cardiac Society)* 2010, 96:838-42.
 89. Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, **Velazquez EJ**, Maggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALSartan In Acute myocardial iNfarcTion Trial (VALIANT). *American Heart Journal* 2010, 160:145-51.
 90. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, **Velazquez EJ**, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt B. Cardiovascular events during differing hypertension therapies in patients with diabetes. *Journal Of The American College Of Cardiology* 2010, 56:77-85.
 91. Pouleur AC, Barkoudah E, Uno H, Skali H, Finn PV, Zelenkofske SL, Belenkov YN, Mareev V, **Velazquez EJ**, Rouleau JL, Maggioni AP, Køber L, Califf RM, McMurray JJ, Pfeffer MA, Solomon SD. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. *Circulation* 2010, 122:597-602.

92. Jones RH, White H, **Velazquez EJ**, Shaw LK, Pietrobon R, Panza JA, Bonow RO, Sopko G, O'Connor CM, Rouleau JL. STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. *Journal Of The American College Of Cardiology* 2010, 56:490-8.
93. Rouleau JL, Michler RE, **Velazquez EJ**, Oh JK, O'Connor CM, Desvigne-Nickens P, Sopko G, Lee KL, Jones RH. The STICH trial: evidence-based conclusions. *European Journal Of Heart Failure* 2010, 12:1028-30.
94. Piccini JP, Zhang M, Pieper K, Solomon SD, Al-Khatib SM, Van de Werf F, Pfeffer MA, McMurray JJ, Califf RM, **Velazquez EJ**. Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. *European Heart Journal* 2010, 31:211-21.
95. Mudrick DW, **Velazquez E**, Borges-Neto S. Does myocardial perfusion imaging provide incremental prognostic information to left ventricular ejection fraction? *Current Cardiology Reports* 2010, 12:155-61.
96. Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, Maggioni A, **Velazquez E**, Califf R, Pfeffer MA, Solomon SD. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. *European Journal Of Heart Failure* 2011, 13:148-53.
97. Samad Z, Kaul P, Shaw LK, Glower DD, **Velazquez EJ**, Douglas PS, Jollis JG. Impact of early surgery on survival of patients with severe mitral regurgitation. *Heart (British Cardiac Society)* 2011, 97:221-4.
98. Samad Z, Atchley AE, Trimble MA, Sun JL, Shaw LK, Pagnanelli R, Chen J, Garcia EV, Iskandrian AE, **Velazquez EJ**, Borges-Neto S. Prevalence and predictors of mechanical dyssynchrony as defined by phase analysis in patients with left ventricular dysfunction undergoing gated SPECT myocardial perfusion imaging. *Journal Of Nuclear Cardiology : Official Publication Of The American Society Of Nuclear Cardiology* 2011, 18:24-30.
99. Weinsaft JW, Kim HW, Crowley AL, Klem I, Shenoy C, Van Assche L, Brosnan R, Shah DJ, **Velazquez EJ**, Parker M, Judd RM, Kim RJ. LV thrombus detection by routine echocardiography: insights into performance characteristics using delayed enhancement CMR. *JACC. Cardiovascular Imaging* 2011, 4:702-12.
100. Bloomfield GS, Hogan JW, Keter A, Sang E, Carter EJ, **Velazquez EJ**, Kimaiyo S. Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western Kenya. *PloS One* 2011, 6:e22288.
101. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, **Velazquez EJ**, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM. Diuretic strategies in patients with acute decompensated heart failure. *The New England Journal Of Medicine* 2011, 364:797-805.
102. **Velazquez EJ**, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL. Coronary-artery bypass surgery in patients with left ventricular dysfunction. *The New England Journal Of Medicine* 2011, 364:1607-16.
103. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozd J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, **Velazquez EJ**, Jones RH, Panza JA. Myocardial viability and survival in ischemic left ventricular dysfunction. *The New England Journal Of Medicine* 2011, 364:1617-25.

104. Swaminathan M, Nicoara A, Phillips-Bute BG, Aeschlimann N, Milano CA, Mackensen GB, Podgoreanu MV, **Velazquez EJ**, Stafford-Smith M, Mathew JP. Utility of a simple algorithm to grade diastolic dysfunction and predict outcome after coronary artery bypass graft surgery. *The Annals Of Thoracic Surgery* 2011, 91:1844-50.
105. Bloomfield GS, Kimaiyo S, Carter EJ, Binanay C, Corey GR, Einterz RM, Tierney WM, **Velazquez EJ**. Chronic noncommunicable cardiovascular and pulmonary disease in sub-Saharan Africa: an academic model for countering the epidemic. *American Heart Journal* 2011, 161:842-7.
106. Ye S, Grunnert M, Thune JJ, Stephenson KM, Uno H, Finn PV, McMurray JJ, **Velazquez EJ**, Califf R, Pfeffer MA, Solomon SD. Circumstances and outcomes of sudden unexpected death in patients with high-risk myocardial infarction: implications for prevention. *Circulation* 2011, 123:2674-80.
107. Verma A, Pfeffer MA, Skali H, Rouleau J, Maggioni A, McMurray JJ, Califf RM, **Velazquez EJ**, Solomon SD. Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. *American Heart Journal* 2011, 161:1156-62.
108. Shah AM, Hung CL, Shin SH, Skali H, Verma A, Ghali JK, Køber L, **Velazquez EJ**, Rouleau JL, McMurray JJ, Pfeffer MA, Solomon SD. Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. *American Heart Journal* 2011, 162:685-91.
109. Jamerson KA, Devereux R, Bakris GL, Dahlöf B, Pitt B, **Velazquez EJ**, Weir M, Kelly RY, Hua TA, Hester A, Weber MA. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. *Hypertension* 2011, 57:174-9.
110. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, **Velazquez EJ**, Hua TA, Kelly RY, Zappe D, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M. Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. *Blood Pressure* 2012, 21:82-7.
111. Siegel B, Sears V, Bretsch JK, Wilson M, Jones KC, Mead H, Hasnain-Wynia R, Ayala RK, Bhalla R, Cornue CM, Emrich CM, Patel P, Setzer JR, Suitonu J, **Velazquez EJ**, Eagle KA, Winniford MD. A quality improvement framework for equity in cardiovascular care: results of a national collaborative. *Journal For Healthcare Quality : Official Publication Of The National Association For Healthcare Quality* 2012, 34:32-42; quiz 42-3.
112. Bloomfield GS, Lagat DK, Akwanalo OC, Carter EJ, Lugogo N, Vedanthan R, **Velazquez EJ**, Kimaiyo S, Sherman CB. Waiting to inhale: An exploratory review of conditions that may predispose to pulmonary hypertension and right heart failure in persons exposed to household air pollution in low- and middle-income countries. *Global Heart* 2012, 7:249-259.
113. **Velazquez EJ**, Williams JB, Yow E, Shaw LK, Lee KL, Phillips HR, O'Connor CM, Smith PK, Jones RH. Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. *The Annals Of Thoracic Surgery* 2012, 93:523-30.
114. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, **Velazquez EJ**, Ibarra JC, Mascette AM, Braunwald E. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. *The New England Journal Of Medicine* 2012, 367:2296-304.
115. Deja MA, Grayburn PA, Sun B, Rao V, She L, Krejca M, Jain AR, Leng Chua Y, Daly R, Senni M, Mokrzycki K, Menicanti L, Oh JK, Michler R, Wróbel K, Lamy A, **Velazquez EJ**, Lee KL, Jones RH.

- Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. *Circulation* 2012, 125:2639-48.
116. Williams ES, Thomas KL, Broderick S, Shaw LK, **Velazquez EJ**, Al-Khatib SM, Daubert JP. Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: results from the Duke Databank for Cardiovascular Disease (DDCD). *American Heart Journal* 2012, 164:434-41.
 117. Risum N, Ali S, Olsen NT, Jons C, Khouri MG, Lauridsen TK, Samad Z, **Velazquez EJ**, Sogaard P, Kisslo J. Variability of global left ventricular deformation analysis using vendor dependent and independent two-dimensional speckle-tracking software in adults. *Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography* 2012, 25:1195-203.
 118. Meris A, Amigoni M, Verma A, Thune JJ, Køber L, **Velazquez E**, McMurray JJ, Pfeffer MA, Califf R, Levine RA, Solomon SD. Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. *Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography* 2012, 25:535-42.
 119. **Velazquez EJ**. Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit?: Myocardial imaging should not exclude patients with ischemic heart failure from coronary revascularization. *Circulation. Cardiovascular Imaging* 2012, 5:271-9; discussion 279.
 120. Jiang W, **Velazquez EJ**, Samad Z, Kuchibhatla M, Martsberger C, Rogers J, Williams R, Kuhn C, Ortel TL, Becker RC, Pristera N, Krishnan R, O'Connor CM. Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial. *American Heart Journal* 2012, 163:20-6.
 121. Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, **Velazquez E**, Jamerson KA. Renal outcomes in hypertensive Black patients at high cardiovascular risk. *Kidney International* 2012, 81:568-76.
 122. Oh JK, Pellikka PA, Panza JA, Biernat J, Attisano T, Manahan BG, Wiste HJ, Lin G, Lee K, Miller FA, Stevens S, Sopko G, She L, **Velazquez EJ**. Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. *Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography* 2012, 25:327-36.
 123. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, **Velazquez EJ**, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. *Lancet* 2013, 381:537-45.
 124. Jiang W, Samad Z, Boyle S, Becker RC, Williams R, Kuhn C, Ortel TL, Rogers J, Kuchibhatla M, O'Connor C, **Velazquez EJ**. Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease. *Journal Of The American College Of Cardiology* 2013, 61:714-22.
 125. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, **Velazquez EJ**, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E. Effect of phosphodiesterase-5 inhibition on exercise

- capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. *JAMA* 2013, 309:1268-77.
126. Panza JA, Holly TA, Asch FM, She L, Pellikka PA, **Velazquez EJ**, Lee KL, Borges-Neto S, Farsky PS, Jones RH, Berman DS, Bonow RO. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. *Journal Of The American College Of Cardiology* 2013, 61:1860-70.
 127. Doenst T, Cleland JG, Rouleau JL, She L, Wos S, Ohman EM, Krzeminska-Pakula M, Airan B, Jones RH, Siepe M, Sopko G, **Velazquez EJ**, Racine N, Gullestad L, Filgueira JL, Lee KL. Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease. *Circulation. Heart Failure* 2013, 6:443-50.
 128. Bloomfield GS, **Velazquez EJ**. HIV and cardiovascular disease in sub-Saharan Africa: the Sutton Law as applied to global health. *Journal Of The American College Of Cardiology* 2013, 61:2395.
 129. Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, **Velazquez EJ**, Pitt B, Jamerson K. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. *The American Journal Of Medicine* 2013, 126:501-8.
 130. Ersbøll M, Valeur N, Mogensen UM, Andersen MJ, Møller JE, **Velazquez EJ**, Hassager C, Søgaaard P, Køber L. Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction. *Journal Of The American College Of Cardiology* 2013, 61:2365-73.
 131. Feldman AM, Mann DL, She L, Bristow MR, Maisel AS, McNamara DM, Walsh R, Lee DL, Wos S, Lang I, Wells G, Drazner MH, Schmedtje JF, Pauly DF, Sueta CA, Di Maio M, Kron IL, **Velazquez EJ**, Lee KL. Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials. *Circulation. Heart Failure* 2013, 6:461-72.
 132. Bloomfield GS, Barasa FA, Doll JA, **Velazquez EJ**. Heart failure in sub-Saharan Africa. *Current Cardiology Reviews* 2013, 9:157-73.
 133. Jiang W, **Velazquez EJ**, Kuchibhatla M, Samad Z, Boyle SH, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, O'Connor C. Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. *JAMA* 2013, 309:2139-49.
 134. Han SY, Palmeri ST, Broderick SH, Hasselblad V, Rendall D, Stevens S, Tenaglia A, **Velazquez E**, Whellan D, Wagner G, Heitner JF. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. *Journal Of Electrocardiology* 2013, 46:45-50.
 135. Michler RE, Rouleau JL, Al-Khalidi HR, Bonow RO, Pellikka PA, Pohost GM, Holly TA, Oh JK, Dagenais F, Milano C, Wrobel K, Pirk J, Ali IS, Jones RH, **Velazquez EJ**, Lee KL, Di Donato M. Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. *The Journal Of Thoracic And Cardiovascular Surgery* 2013, 146:1139-1145.e6.
 136. Oh JK, **Velazquez EJ**, Menicanti L, Pohost GM, Bonow RO, Lin G, Hellkamp AS, Ferrazzi P, Wos S, Rao V, Berman D, Bochenek A, Cherniavsky A, Rogowski J, Rouleau JL, Lee KL. Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. *European Heart Journal* 2013, 34:39-47.
 137. Ersbøll M, Valeur N, Andersen MJ, Mogensen UM, Vinther M, Svendsen JH, Møller JE, Kisslo J, **Velazquez EJ**, Hassager C, Søgaaard P, Køber L. Early echocardiographic deformation analysis for the

- prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction. *JACC. Cardiovascular Imaging* 2013, 6:851-60.
138. Givertz MM, Mann DL, Lee KL, Ibarra JC, **Velazquez EJ**, Hernandez AF, Mascette AM, Braunwald E. Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. *Circulation. Heart Failure* 2013, 6:862-8.
 139. Risum N, Williams ES, Khouri MG, Jackson KP, Olsen NT, Jons C, Storm KS, **Velazquez EJ**, Kisslo J, Bruun NE, Sogaard P. Mechanical dyssynchrony evaluated by tissue Doppler cross-correlation analysis is associated with long-term survival in patients after cardiac resynchronization therapy. *European Heart Journal* 2013, 34:48-56.
 140. Golba K, Mokrzycki K, Drozd J, Cherniavsky A, Wrobel K, Roberts BJ, Haddad H, Maurer G, Yii M, Asch FM, Handschumacher MD, Holly TA, Przybylski R, Kron I, Schaff H, Aston S, Horton J, Lee KL, **Velazquez EJ**, Grayburn PA. Mechanisms of functional mitral regurgitation in ischemic cardiomyopathy determined by transesophageal echocardiography (from the Surgical Treatment for Ischemic Heart Failure Trial). *The American Journal Of Cardiology* 2013, 112:1812-8.
 141. Jiang W, O'Connor CM, **Velazquez EJ**. Therapy for mental stress-induced myocardial ischemia--reply. *JAMA* 2013, 310:1401-2.
 142. Boyle SH, Samad Z, Becker RC, Williams R, Kuhn C, Ortel TL, Kuchibhatla M, Prybol K, Rogers J, O'Connor C, **Velazquez EJ**, Jiang W. Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease. *Psychosomatic Medicine* 2013, 75:822-31.
 143. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, **Velazquez EJ**, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. *JAMA* 2013, 310:2533-43.
 144. Carson P, Wertheimer J, Miller A, O'Connor CM, Pina IL, Selzman C, Sueta C, She L, Greene D, Lee KL, Jones RH, **Velazquez EJ**. The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. *JACC. Heart Failure* 2013, 1:400-8.
 145. Bloomfield GS, Hogan JW, Keter A, Holland TL, Sang E, Kimaiyo S, **Velazquez EJ**. Blood pressure level impacts risk of death among HIV seropositive adults in Kenya: a retrospective analysis of electronic health records. *BMC Infectious Diseases* 2014, 14:284.
 146. Douglas PS, Hoffmann U, Lee KL, Mark DB, Al-Khalidi HR, Anstrom K, Dolor RJ, Kosinski A, Krucoff MW, Mudrick DW, Patel MR, Picard MH, Udelson JE, **Velazquez EJ**, Cooper L. PROspective Multicenter Imaging Study for Evaluation of chest pain: rationale and design of the PROMISE trial. *American Heart Journal* 2014, 167:796-803.e1.
 147. Bloomfield GS, Vedanthan R, Vasudevan L, Kithei A, Were M, **Velazquez EJ**. Mobile health for non-communicable diseases in Sub-Saharan Africa: a systematic review of the literature and strategic framework for research. *Globalization And Health* 2014, 10:49.
 148. Stewart RA, Szalewska D, She L, Lee KL, Drazner MH, Lubiszewska B, Kosevic D, Ruengsakulrach P, Nicolau JC, Coutu B, Choudhary SK, Mark DB, Cleland JG, Piña IL, **Velazquez EJ**, Rynkiewicz A, White H. Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure). *JACC. Heart Failure* 2014, 2:335-43.

149. Panza JA, **Velazquez EJ**, She L, Smith PK, Nicolau JC, Favaloro RR, Gradinac S, Chrzanowski L, Prabhakaran D, Howlett JG, Jasinski M, Hill JA, Szwed H, Larbalestier R, Desvigne-Nickens P, Jones RH, Lee KL, Rouleau JL. Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]. *Journal Of The American College Of Cardiology* 2014, 64:553-61.
150. Bloomfield GS, Khazanie P, Morris A, Rabadán-Diehl C, Benjamin LA, Murdoch D, Radcliff VS, **Velazquez EJ**, Hicks C. HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research. *Journal Of Acquired Immune Deficiency Syndromes (1999)* 2014, 67 Suppl 1:S40-53.
151. Holly TA, Bonow RO, Arnold JM, Oh JK, Varadarajan P, Pohost GM, Haddad H, Jones RH, **Velazquez EJ**, Birkenfeld B, Asch FM, Malinowski M, Barretto R, Kalil RA, Berman DS, Sun JL, Lee KL, Panza JA. Myocardial viability and impact of surgical ventricular reconstruction on outcomes of patients with severe left ventricular dysfunction undergoing coronary artery bypass surgery: results of the Surgical Treatment for Ischemic Heart Failure trial. *The Journal Of Thoracic And Cardiovascular Surgery* 2014, 148:2677-84.e1.
152. Mark DB, Knight JD, **Velazquez EJ**, Wasilewski J, Howlett JG, Smith PK, Spertus JA, Rajda M, Yadav R, Hamman BL, Malinowski M, Naik A, Rankin G, Harding TM, Drew LA, Desvigne-Nickens P, Anstrom KJ. Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial. *Annals Of Internal Medicine* 2014, 161:392-9.
153. Castleberry AW, Williams JB, Daneshmand MA, Honeycutt E, Shaw LK, Samad Z, Lopes RD, Alexander JH, Mathew JP, **Velazquez EJ**, Milano CA, Smith PK. Surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience. *Circulation* 2014, 129:2547-56.
154. Khouri MG, Hornsby WE, Risum N, **Velazquez EJ**, Thomas S, Lane A, Scott JM, Koelwyn GJ, Herndon JE, Mackey JR, Douglas PS, Jones LW. Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. *Breast Cancer Research And Treatment* 2014, 143:531-9.
155. Ersbøll M, Al Enezi F, Samad Z, Sedberry B, Boyle SH, O'Connor C, Jiang W, **Velazquez EJ**. Impaired resting myocardial annular velocities are independently associated with mental stress-induced ischemia in coronary heart disease. *JACC. Cardiovascular Imaging* 2014, 7:351-61.
156. Rajagopal S, Forsha DE, Risum N, Hornik CP, Poms AD, Fortin TA, Tapson VF, **Velazquez EJ**, Kisslo J, Samad Z. Comprehensive assessment of right ventricular function in patients with pulmonary hypertension with global longitudinal peak systolic strain derived from multiple right ventricular views. *Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography* 2014, 27:657-665.e3.
157. Lewis EF, Li Y, Pfeffer MA, Solomon SD, Weinfurt KP, **Velazquez EJ**, Califf RM, Rouleau JL, Kober L, White HD, Schulman KA, Reed SD. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). *JACC. Heart Failure* 2014, 2:159-65.
158. Vedanthan R, Kamano JH, Horowitz CR, Ascheim D, **Velazquez EJ**, Kimaiyo S, Fuster V. Nurse management of hypertension in rural western Kenya: implementation research to optimize delivery. *Annals Of Global Health* 2014, 80:5-12.

159. Vedanthan R, Kamano JH, Naanyu V, DeLong AK, Were MC, Finkelstein EA, Menya D, Akwanalo CO, Bloomfield GS, Binanay CA, **Velazquez EJ**, Hogan JW, Horowitz CR, Inui TS, Kimaiyo S, Fuster V. Optimizing linkage and retention to hypertension care in rural Kenya (LARK hypertension study): study protocol for a randomized controlled trial. *Trials* 2014, 15:143.
160. Lagat DK, DeLong AK, Wellenius GA, Carter EJ, Bloomfield GS, **Velazquez EJ**, Hogan J, Kimaiyo S, Sherman CB. Factors associated with isolated right heart failure in women: a pilot study from western Kenya. *Global Heart* 2014, 9:249-54.
161. Samad Z, Boyle S, Erbsoll M, Vora AN, Zhang Y, Becker RC, Williams R, Kuhn C, Ortel TL, Rogers JG, O'Connor CM, **Velazquez EJ**, Jiang W. Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study. *Journal Of The American College Of Cardiology* 2014, 64:1669-78.
162. Jiang W, Boyle SH, Ortel TL, Samad Z, **Velazquez EJ**, Harrison RW, Wilson J, Kuhn C, Williams RB, O'Connor CM, Becker RC. Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study. *American Heart Journal* 2015, 169:496-507.e1.
163. Castleberry AW, Williams JB, Daneshmand MA, Honeycutt E, Shaw LK, Samad Z, Lopes RD, Alexander JH, Mathew JP, **Velazquez EJ**, Milano CA, Smith PK. Response to letter regarding article, "surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience". *Circulation* 2015, 131:e378-9.
164. Holmqvist F, Thomas KL, Broderick S, Erbsøll M, Singh D, Chiswell K, Shaw LK, Hegland DD, **Velazquez EJ**, Daubert JP. Clinical outcome as a function of the PR-interval-there is virtue in moderation: data from the Duke Databank for cardiovascular disease. *Europace : European Pacing, Arrhythmias, And Cardiac Electrophysiology : Journal Of The Working Groups On Cardiac Pacing, Arrhythmias, And Cardiac Cellular Electrophysiology Of The European Society Of Cardiology* 2015, 17:978-85.
165. Samad Z, Shaw LK, Phelan M, Erbsoll M, Risum N, Al-Khalidi HR, Glower DD, Milano CA, Alexander JH, O'Connor CM, Wang A, **Velazquez EJ**. Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction. *European Heart Journal* 2015, 36:2733-41.
166. Binanay CA, Akwanalo CO, Aruasa W, Barasa FA, Corey GR, Crowe S, Esamai F, Einterz R, Foster MC, Gardner A, Kibosia J, Kimaiyo S, Koech M, Korir B, Lawrence JE, Lukas S, Manji I, Maritim P, Ogaro F, Park P, Pastakia SD, Sugut W, Vedanthan R, Yanoh R, **Velazquez EJ**, Bloomfield GS. Building Sustainable Capacity for Cardiovascular Care at a Public Hospital in Western Kenya. *Journal Of The American College Of Cardiology* 2015, 66:2550-60.
167. Parikh KS, Rajagopal S, Arges K, Ahmad T, Sivak J, Kaul P, Shah SH, Tapson V, **Velazquez EJ**, Douglas PS, Samad Z. Use of outcome measures in pulmonary hypertension clinical trials. *American Heart Journal* 2015, 170:419-29.e3.
168. Steinberg BA, Schulte PJ, Hofmann P, Erbsøll M, Alexander JH, Broderick-Forsgren K, Anstrom KJ, Granger CB, Piccini JP, **Velazquez EJ**, Shah BR. Outcomes after nonemergent electrical cardioversion for atrial arrhythmias. *The American Journal Of Cardiology* 2015, 115:1407-14.
169. **Velazquez EJ**, Bonow RO. Revascularization in severe left ventricular dysfunction. *Journal Of The American College Of Cardiology* 2015, 65:615-24.
170. Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, **Velazquez EJ**, O'Connor CM. A reappraisal of loop diuretic choice in heart failure patients. *American Heart Journal* 2015, 169:323-33.

171. Burroughs Peña M, Romero KM, **Velazquez EJ**, Davila-Roman VG, Gilman RH, Wise RA, Miranda JJ, Checkley W. Relationship between daily exposure to biomass fuel smoke and blood pressure in high-altitude Peru. *Hypertension* 2015, 65:1134-40.
172. Bloomfield GS, Wang TY, Boulware LE, Califf RM, Hernandez AF, **Velazquez EJ**, Peterson ED, Li JS. Implementation of management strategies for diabetes and hypertension: from local to global health in cardiovascular diseases. *Global Heart* 2015, 10:31-8.
173. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, Cole J, Dolor RJ, Fordyce CB, Huang M, Khan MA, Kosinski AS, Krucoff MW, Malhotra V, Picard MH, Udelson JE, **Velazquez EJ**, Yow E, Cooper LS, Lee KL. Outcomes of anatomical versus functional testing for coronary artery disease. *The New England Journal Of Medicine* 2015, 372:1291-300.
174. Choi JO, Daly RC, Lin G, Lahr BD, Wiste HJ, Beaver TM, Iacovoni A, Malinowski M, Friedrich I, Rouleau JL, Favalaro RR, Sopko G, Lang IM, White HD, Milano CA, Jones RH, Lee KL, **Velazquez EJ**, Oh JK. Impact of surgical ventricular reconstruction on sphericity index in patients with ischaemic cardiomyopathy: follow-up from the STICH trial. *European Journal Of Heart Failure* 2015, 17:453-63.
175. Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, Eisenstein EL, Anstrom KJ, O'Connor CM, **Velazquez EJ**. Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital. *Journal Of Cardiovascular Pharmacology* 2015, 65:438-43.
176. Hannink LG, Wagner GS, Kisslo J, Alenezi FA, Shaw LK, Hofmann P, Zusterzeel R, Phelan M, **Velazquez EJ**, Gorgels AP. Influence of QRS infarct score and QRS duration prior to transcatheter aortic valve replacement on follow-up left ventricular end systolic volume in patients with new persistent left bundle branch block. *Journal Of Electrocardiology* 2015, 48:637-42.
177. Boyle SH, Matson WR, **Velazquez EJ**, Samad Z, Williams RB, Sharma S, Thomas B, Wilson JL, O'Connor C, Jiang W. Metabolomics analysis reveals insights into biochemical mechanisms of mental stress-induced left ventricular dysfunction. *Metabolomics : Official Journal Of The Metabolomic Society* 2015, 11:571-582.
178. MacDonald MR, She L, Doenst T, Binkley PF, Rouleau JL, Tan RS, Lee KL, Miller AB, Sopko G, Szalewska D, Waclawiw MA, Dabrowski R, Castelvechio S, Adlbrecht C, Michler RE, Oh JK, **Velazquez EJ**, Petrie MC. Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. *European Journal Of Heart Failure* 2015, 17:725-34.
179. Holly TA, Bonow RO, **Velazquez EJ**, Panza JA. A balanced assessment of the STICH trial. *The Journal Of Thoracic And Cardiovascular Surgery* 2015, 149:1683-4.
180. Grayburn PA, She L, Roberts BJ, Golba KS, Mokrzycki K, Drozd J, Cherniavsky A, Przybylski R, Wrobel K, Asch FM, Holly TA, Haddad H, Yii M, Maurer G, Kron I, Schaff H, **Velazquez EJ**, Oh JK. Comparison of Transesophageal and Transthoracic Echocardiographic Measurements of Mechanism and Severity of Mitral Regurgitation in Ischemic Cardiomyopathy (from the Surgical Treatment of Ischemic Heart Failure Trial). *The American Journal Of Cardiology* 2015, 116:913-8.
181. Buggey J, Mentz RJ, DeVore AD, **Velazquez EJ**. Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. *Journal Of Cardiac Failure* 2015, 21:741-50.
182. Ersboll M, Samad Z, Al Enezi F, Kisslo J, Schulte PJ, Shaw LK, Køber L, Harrison JK, Bashore T, Brennan M, **Velazquez EJ**. Temporal Trends in Disease Severity and Predicted Surgical Risk at the Time of Referral for Echocardiography in Patients Diagnosed with Aortic Stenosis. *Critical Pathways In Cardiology* 2015, 14:103-9.

183. Khouri MG, Klein MR, **Velazquez EJ**, Jones LW. Current and emerging modalities for detection of cardiotoxicity in cardio-oncology. *Future Cardiology* 2015, 11:471-84.
184. Bloomfield GS, Alenezi F, Barasa FA, Lumsden R, Mayosi BM, **Velazquez EJ**. Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries. *JACC. Heart Failure* 2015, 3:579-90.
185. Wrobel K, Stevens SR, Jones RH, Selzman CH, Lamy A, Beaver TM, Djokovic LT, Wang N, **Velazquez EJ**, Sopko G, Kron IL, DiMaio JM, Michler RE, Lee KL, Yii M, Leng CY, Zembala M, Rouleau JL, Daly RC, Al-Khalidi HR. Influence of Baseline Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left Ventricular Dysfunction: Results From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. *Circulation* 2015, 132:720-30.
186. Bonow RO, Castelvechio S, Panza JA, Berman DS, **Velazquez EJ**, Michler RE, She L, Holly TA, Desvigne-Nickens P, Kosevic D, Rajda M, Chrzanowski L, Deja M, Lee KL, White H, Oh JK, Doenst T, Hill JA, Rouleau JL, Menicanti L. Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. *JACC. Cardiovascular Imaging* 2015, 8:1121-1129.
187. Bloomfield GS, Temu TM, Akwanalo CO, Chen PS, Emonyi W, Heckbert SR, Koech MM, Manji I, Shen C, Vatta M, **Velazquez EJ**, Wessel J, Kimaiyo S, Inui TS. Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL). *American Heart Journal* 2015, 170:455-64.e5.
188. Mentz RJ, **Velazquez EJ**, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. *Future Cardiology* 2015, 11:585-95.
189. Jolicœur EM, Dunning A, Castelvechio S, Dabrowski R, Waclawiw MA, Petrie MC, Stewart R, Jhund PS, Desvigne-Nickens P, Panza JA, Bonow RO, Sun B, San TR, Al-Khalidi HR, Rouleau JL, **Velazquez EJ**, Cleland JGF. Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. *Journal Of The American College Of Cardiology* 2015, 66:2092-2100.
190. **Velazquez EJ**, Samad Z, Al-Khalidi HR, Sangli C, Grayburn PA, Massaro JM, Stevens SR, Feldman TE, Krucoff MW. The MitraClip and survival in patients with mitral regurgitation at high risk for surgery: A propensity-matched comparison. *American Heart Journal* 2015, 170:1050-1059.e3.
191. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, **Velazquez EJ**, Shah MR, Braunwald E. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. *The New England Journal Of Medicine* 2015, 373:2314-24.
192. Kukulski T, She L, Racine N, Gradinac S, Panza JA, **Velazquez EJ**, Chan K, Petrie MC, Lee KL, Pellikka PA, Romanov A, Biernat J, Rouleau JL, Batlle C, Rogowski J, Ferrazzi P, Zembala M, Oh JK. Implication of right ventricular dysfunction on long-term outcome in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting with or without surgical ventricular reconstruction. *The Journal Of Thoracic And Cardiovascular Surgery* 2015, 149:1312-21.
193. Ersboll M, Schulte PJ, Al Enezi F, Shaw L, Køber L, Kisslo J, Siddiqui I, Piccini J, Glower D, Harrison JK, Bashore T, Risum N, Jollis JG, **Velazquez EJ**, Samad Z. Predictors and progression of aortic stenosis in patients with preserved left ventricular ejection fraction. *The American Journal Of Cardiology* 2015, 115:86-92.

194. Feldman AM, She L, McNamara DM, Mann DL, Bristow MR, Maisel AS, Wagner DR, Andersson B, Chiariello L, Hayward CS, Hendry P, Parker JD, Racine N, Selzman CH, Senni M, Stepinska J, Zembala M, Rouleau J, **Velazquez EJ**, Lee KL. Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials. *Cardiology* 2015, 130:69-81.
195. Lam CS, McEntegart M, Claggett B, Liu J, Skali H, Lewis E, Køber L, Rouleau J, **Velazquez E**, Califf R, McMurray JJ, Pfeffer M, Solomon S. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). *European Journal Of Heart Failure* 2015, 17:301-12.
196. Weber MA, Bloch M, Bakris GL, Weir MR, Zappe DH, Dahlof B, **Velazquez EJ**, Pitt B, Basile JN, Jamerson K, Hua TA. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. *Journal Of Clinical Hypertension (Greenwich, Conn.)* 2016, 18:299-307.
197. Sivak JA, Vora AN, Navar AM, Schulte PJ, Crowley AL, Kisslo J, Corey GR, Liao L, Wang A, **Velazquez EJ**, Samad Z. An Approach to Improve the Negative Predictive Value and Clinical Utility of Transthoracic Echocardiography in Suspected Native Valve Infective Endocarditis. *Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography* 2016, 29:315-22.
198. Samad Z, Vora AN, Dunning A, Schulte PJ, Shaw LK, Al-Enezi F, Ersboll M, McGarrah RW, Vavalle JP, Shah SH, Kisslo J, Glower D, Harrison JK, **Velazquez EJ**. Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction. *European Heart Journal* 2016, 37:2276-86.
199. Lopes RD, Pieper KS, Stevens SR, Solomon SD, McMurray JJ, Pfeffer MA, Leimberger JD, **Velazquez EJ**. Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. *Journal Of The American Heart Association* 2016, 5.
200. Hunter WG, Kelly JP, McGarrah RW, Khouri MG, Craig D, Haynes C, Ilkayeva O, Stevens RD, Bain JR, Muehlbauer MJ, Newgard CB, Felker GM, Hernandez AF, **Velazquez EJ**, Kraus WE, Shah SH. Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. *Journal Of The American Heart Association* 2016, 5.
201. Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, Hill JA, Lee KL, Rouleau JL, Prior DL, Ali IS, Maddury J, Golba KS, White HD, Carson P, Chrzanowski L, Romanov A, Miller AB, **Velazquez EJ**. Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). *Circulation* 2016, 134:1314-1324.
202. Burroughs Peña MS, Dunning A, Schulte PJ, Durham MT, Kussin P, Checkley W, **Velazquez EJ**. Pulmonary function and adverse cardiovascular outcomes: Can cardiac function explain the link? *Respiratory Medicine* 2016, 121:4-12.
203. Dahhan T, Siddiqui I, Tapson VF, **Velazquez EJ**, Sun S, Davenport CA, Samad Z, Rajagopal S. Clinical and echocardiographic predictors of mortality in acute pulmonary embolism. *Cardiovascular Ultrasound* 2016, 14:44.

204. Samad Z, **Velazquez EJ**. Functional Mitral Regurgitation: Appraising the Evidence Behind Recommended Treatment Strategies. *Current Cardiology Reports* 2016, 18:128.
205. Klein MR, Kiefer TL, **Velazquez EJ**. Platypnea-Orthodeoxia Syndrome: To Shunt or Not to Shunt, That is the Question. *Texas Heart Institute Journal / From The Texas Heart Institute Of St. Luke's Episcopal Hospital, Texas Children's Hospital* 2016, 43:264-6.
206. Garber AM, Mentz RJ, Al-Khalidi HR, Shaw LK, Fiuzat M, O'Connor CM, **Velazquez EJ**. Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction. *Journal Of Thrombosis And Thrombolysis* 2016, 41:365-73.
207. Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, **Velazquez EJ**, O'Connor CM. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). *The American Journal Of Cardiology* 2016, 117:404-11.
208. DeVore AD, Schulte PJ, Mentz RJ, Hardy NC, Kelly JP, **Velazquez EJ**, Maya JF, Kielhorn A, Patel HK, Reed SD, Hernandez AF. Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. *The American Journal Of Cardiology* 2016, 117:946-51.
209. Samad Z, Minter S, Armour A, Tinnemore A, Sivak JA, Sedberry B, Strub K, Horan SM, Harrison JK, Kisslo J, Douglas PS, **Velazquez EJ**. Implementing a Continuous Quality Improvement Program in a High-Volume Clinical Echocardiography Laboratory: Improving Care for Patients With Aortic Stenosis. *Circulation. Cardiovascular Imaging* 2016, 9.
210. **Velazquez EJ**, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne-Nickens P, Sopko G, Rouleau JL. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. *The New England Journal Of Medicine* 2016, 374:1511-20.
211. Redfield MM, **Velazquez EJ**, Braunwald E. Nitrates in Heart Failure with Preserved Ejection Fraction. *The New England Journal Of Medicine* 2016, 374:1589.
212. Bloomfield GS, DeLong AK, Akwanalo CO, Hogan JW, Carter EJ, Aswa DF, Binanay C, Koech M, Kimaiyo S, **Velazquez EJ**. Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure: A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya. *Global Heart* 2016, 11:97-107.
213. Samsky MD, DeVore AD, Durkin M, Stout JE, **Velazquez EJ**, Milano CA. Getting to a Man's Heart through His Colon. *Texas Heart Institute Journal / From The Texas Heart Institute Of St. Luke's Episcopal Hospital, Texas Children's Hospital* 2016, 43:168-70.
214. Abdul-Rahim AH, Docherty KF, Skali H, Køber L, Dickstein K, Maggioni AP, Mareev V, Zannad F, **Velazquez EJ**, Califf RM, Pfeffer MA, Solomon SD, Lees KR, McMurray JJ. Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. *European Stroke Journal* 2016, 1:93-100.
215. Pokorney SD, Miller AL, Chen AY, Thomas L, Fonarow GC, de Lemos JA, Al-Khatib SM, **Velazquez EJ**, Peterson ED, Wang TY. Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. *Circulation* 2017, 135:38-47.
216. Barasa FA, Vedanthan R, Pastakia SD, Crowe SJ, Aruasa W, Sugut WK, White R, Ogola ES, Bloomfield GS, **Velazquez EJ**. Approaches to Sustainable Capacity Building for Cardiovascular Disease Care in Kenya. *Cardiology Clinics* 2017, 35:145-152.

217. DeVore AD, **Velazquez EJ**. Rethinking Revascularization in Left Ventricular Systolic Dysfunction. *Circulation. Heart Failure* 2017, 10.
218. Wyrembak J, Campbell KB, Steinberg BA, Bahnson TD, Daubert JP, **Velazquez EJ**, Samad Z, Atwater BD. Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation. *The American Journal Of Cardiology* 2017, 119:1017-1022.
219. Rao MP, Al-Khatib SM, Pokorney SD, She L, Romanov A, Nicolau JC, Lee KL, Carson P, Selzman CH, Stepinska J, Cleland JG, Tungsubutra W, Desvigne-Nickens PM, Sueta CA, Siepe M, Lang I, Feldman AM, Yii M, Rouleau JL, **Velazquez EJ**. Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure). *Circulation* 2017, 135:1136-1144.
220. DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, Anstrom KJ, Hernandez AF, **Velazquez EJ**. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. *European Journal Of Heart Failure* 2017, 19:893-900.
221. Pai RG, Varadarajan P, Rouleau JL, Stebbins AL, **Velazquez EJ**, Al-Khalidi HR, Pohost GM. Value of Cardiovascular Magnetic Resonance Imaging-Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. *JAMA Cardiology* 2017, 2:577-579.
222. Randolph TC, Broderick S, Shaw LK, Chiswell K, Mentz RJ, Kutiyifa V, **Velazquez EJ**, Gilliam FR, Thomas KL. Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction. *Journal Of The American Heart Association* 2017, 6.
223. Broderick-Forsgren K, Davenport CA, Sivak JA, Hargett CW, Foster MC, Monteagudo A, Armour A, Rajagopal S, Arges K, **Velazquez EJ**, Samad Z. Improving on the diagnostic characteristics of echocardiography for pulmonary hypertension. *The International Journal Of Cardiovascular Imaging* 2017, 33:1341-1349.
224. DeVore AD, Alenezi F, Krishnamoorthy A, Ersboll M, Samsky MD, Schulte PJ, Patel CB, Rogers JG, Milano CA, **Velazquez EJ**, Khouri MG. Assessment of cardiac allograft systolic function by global longitudinal strain: From donor to recipient. *Clinical Transplantation* 2017, 31.
225. Banks A, Broderick S, Chiswell K, Shaw L, Devore A, Fiuzat M, O'Connor C, Felker GM, **Velazquez E**, Mentz R. Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease). *The American Journal Of Cardiology* 2017, 119:1703-1709.
226. Bhatt AS, Ambrosy AP, **Velazquez EJ**. Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. *Current Cardiology Reports* 2017, 19:71.
227. Lekavich CL, Barksdale DJ, Wu JR, Neelon V, Crandell J, **Velazquez EJ**. Measures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis. *Journal Of Cardiac Failure* 2017, 23:659-665.
228. Lu MT, Douglas PS, Udelson JE, Adami E, Ghoshhajra BB, Picard MH, Roberts R, Lee KL, Einstein AJ, Mark DB, **Velazquez EJ**, Carter W, Ridner M, Al-Khalidi HR, Hoffmann U. Safety of coronary CT angiography and functional testing for stable chest pain in the PROMISE trial: A randomized comparison of test complications, incidental findings, and radiation dose. *Journal Of Cardiovascular Computed Tomography* 2017, 11:373-382.

229. Sze E, Dunning A, Loring Z, Atwater BD, Chiswell K, Daubert JP, Kisslo JA, Mark DB, **Velazquez EJ**, Samad Z. Comparison of Incidence of Left Ventricular Systolic Dysfunction Among Patients With Left Bundle Branch Block Versus Those With Normal QRS Duration. *The American Journal Of Cardiology* 2017, 120:1990-1997.
230. Alenezi F, Brummett BH, Boyle SH, Samad Z, Babyak MA, Alzaeim N, Wilson J, Romano MMD, Sun JL, Ersboll M, O'Connor CM, **Velazquez EJ**, Jiang W. Usefulness of Myocardial Annular Velocity Change During Mental Stress to Predict Cardiovascular Outcome in Patients With Coronary Artery Disease (From the Responses of Mental Stress-Induced Myocardial Ischemia to Escitalopram Treatment Trial). *The American Journal Of Cardiology* 2017, 120:1495-1500.
231. Temu TM, Lane KA, Shen C, Ng'ang'a L, Akwanalo CO, Chen PS, Emonyi W, Heckbert SR, Koech MM, Manji I, Vatta M, **Velazquez EJ**, Wessel J, Kimaiyo S, Inui TS, Bloomfield GS. Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya. *PLoS One* 2017, 12:e0185204.
232. Samad Z, Sivak JA, Phelan M, Schulte PJ, Patel U, **Velazquez EJ**. Prevalence and Outcomes of Left-Sided Valvular Heart Disease Associated With Chronic Kidney Disease. *Journal Of The American Heart Association* 2017, 6.
233. Buggey J, Alenezi F, Yoon HJ, Phelan M, DeVore AD, Khouri MG, Schulte PJ, **Velazquez EJ**. Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. *ESC Heart Failure* 2017, 4:432-439.
234. Sun JL, Boyle SH, Samad Z, Babyak MA, Wilson JL, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, O'Connor CM, **Velazquez EJ**, Jiang W. Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. *European Journal Of Preventive Cardiology* 2017, 24:591-599.
235. Feigal JP, Boyle SH, Samad Z, **Velazquez EJ**, Wilson JL, Becker RC, Williams RB, Kuhn CM, Ortel TL, Rogers JG, O'Connor CM, Jiang W. Associations between positive emotional well-being and stress-induced myocardial ischemia: Well-being scores predict exercise-induced ischemia. *Journal Of Psychosomatic Research* 2017, 93:14-18.
236. Burroughs Peña MS, **Velazquez EJ**, Rivera JD, Alenezi F, Wong C, Grigsby M, Davila-Roman VG, Gilman RH, Miranda JJ, Checkley W. Biomass fuel smoke exposure was associated with adverse cardiac remodeling and left ventricular dysfunction in Peru. *Indoor Air* 2017, 27:737-745.
237. Giannini C, D'ascenzo F, Fiorelli F, Spontoni P, Swaans MJ, **Velazquez EJ**, Armeni P, Adamo M, De Carlo M, Petronio AS. A meta-analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients. *ESC Heart Failure* 2018, 5:1150-1158.
238. Agarwal A, Kirwa K, Eliot MN, Alenezi F, Menya D, Mitter SS, **Velazquez EJ**, Vedanthan R, Wellenius GA, Bloomfield GS. Household Air Pollution Is Associated with Altered Cardiac Function among Women in Kenya. *American Journal Of Respiratory And Critical Care Medicine* 2018, 197:958-961.
239. Borlaug BA, **Velazquez EJ**. On Books, Covers, and Judgments in Heart Failure. *JACC. Cardiovascular Imaging* 2018, 11:1747-1749.
240. Pokorney SD, Al-Khatib SM, Sun JL, Schulte P, O'Connor CM, Teerlink JR, Armstrong PW, Ezekowitz JA, Starling RC, Voors AA, **Velazquez EJ**, Hernandez AF, Mentz RJ. Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. *European Journal Of Heart Failure* 2018, 20:525-532.

241. Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, **Velazquez E**, Weber M, Zappe DH, Hau T, Jamerson KA. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. *Journal Of The American Heart Association* 2018, 7.
242. Sze E, Samad Z, Dunning A, Campbell KB, Loring Z, Atwater BD, Chiswell K, Kisslo JA, **Velazquez EJ**, Daubert JP. Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left Bundle Branch Block. *Journal Of The American College Of Cardiology* 2018, 71:306-317.
243. Bouabdallaoui N, Stevens SR, Doenst T, Wrobel K, Bouchard D, Deja MA, Michler RE, Chua YL, Kalil RAK, Selzman CH, Daly RC, Sun B, Djokovic LT, Sopko G, **Velazquez EJ**, Rouleau JL, Lee KL, Al-Khalidi HR. Impact of Intubation Time on Survival following Coronary Artery Bypass Grafting: Insights from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. *Journal Of Cardiothoracic And Vascular Anesthesia* 2018, 32:1256-1263.
244. Piña IL, Zheng Q, She L, Szwed H, Lang IM, Farsky PS, Castelveccchio S, Biernat J, Paraforos A, Kosevic D, Favaloro LE, Nicolau JC, Varadarajan P, **Velazquez EJ**, Pai RG, Cyrille N, Lee KL, Desvigne-Nickens P. Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization: Results From the STICH Trial (Surgical Treatment for Ischemic Heart Failure). *Circulation* 2018, 137:771-780.
245. **Velazquez EJ**, Petrie MC. CABG or PCI for Diabetic Patients With Left Ventricular Dysfunction: Closing in on the Truth? *Journal Of The American College Of Cardiology* 2018, 71:828-831.
246. Butler J, Kalogeropoulos AP, Anstrom KJ, Hsue PY, Kim RJ, Scherzer R, Shah SJ, Shah SH, **Velazquez EJ**, Hernandez AF, Desvigne-Nickens P, Braunwald E. Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. *Journal Of Cardiac Failure* 2018, 24:255-265.
247. Il'Giovine ZJ, Mulder H, Chiswell K, Arges K, Tomfohr J, Hashmi A, **Velazquez EJ**, Kisslo JA, Samad Z, Rajagopal S. Right Ventricular Longitudinal Strain Reproducibility Using Vendor-Dependent and Vendor-Independent Software. *Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography* 2018, 31:721-732.e5.
248. Stewart RAH, Szalewska D, Stebbins A, Al-Khalidi HR, Cleland JGH, Rynkiewicz A, Drazner MH, White HD, Mark DB, Roy A, Kosevic D, Rajda M, Jasinski M, Leng CY, Tungsubutra W, Desvigne-Nickens P, **Velazquez EJ**, Petrie MC. Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. *Open Heart* 2018, 5:e000752.
249. **Velazquez EJ**, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E. Rationale and design of the comParlson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. *American Heart Journal* 2018, 198:145-151.
250. Ambrosy AP, **Velazquez EJ**. Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. *American Heart Journal* 2018, 199:176-177.
251. Ohman EM, **Velazquez EJ**. Revascularization for Heart Failure: Can We Do Better? *JACC. Heart Failure* 2018, 6:527-529.
252. Okeke NL, Alenezi F, Bloomfield GS, Dunning A, Clement ME, Shah SH, Naggie S, **Velazquez EJ**. Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort. *Journal Of Cardiac Failure* 2018, 24:496-503.

253. Friedman DJ, Fudim M, Overton R, Shaw LK, Patel D, Pokorney SD, **Velazquez EJ**, Al-Khatib SM. The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. *American Heart Journal* 2018, 201:17-24.
254. Samad Z, Shaw LK, Phelan M, Glower DD, Ersboll M, Toptine JH, Alexander JH, Kisslo JA, Wang A, Mark DB, **Velazquez EJ**. Long-term outcomes of mitral regurgitation by type and severity. *American Heart Journal* 2018, 203:39-48.
255. Andersson B, She L, Tan RS, Jeemon P, Mokrzycki K, Siepe M, Romanov A, Favaloro LE, Djokovic LT, Raju PK, Betlejewski P, Racine N, Ostrzycki A, Nawarawong W, Das S, Rouleau JL, Sopko G, Lee KL, **Velazquez EJ**, Panza JA. The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial. *European Heart Journal* 2018, 39:3464-3471.
256. Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, Hernandez AF, Michael Felker G, Cooper LB, Lala A, Vader J, Groake JD, Borlaug BA, **Velazquez EJ**. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. *ESC Heart Failure* 2018, 5:1035-1043.
257. Crowley AL, Yow E, Rabineau D, Norris C, White J, Daubert MA, **Velazquez EJ**, Barnhart H, Krucoff MW, Rao SV, Douglas PS. The Impact of a Rigorous Quality Program on 3D Echocardiography Data Quality in an International Multisite Randomized Trial. *JACC. Cardiovascular Imaging* 2018, 11:1918-1920.
258. Minter S, Armour A, Tinnemore A, Strub K, Crowley AL, Bloomfield GS, Alexander JH, Douglas PS, Kisslo JA, **Velazquez EJ**, Samad Z. Crowdsourcing consensus: proposal of a novel method for assessing accuracy in echocardiography interpretation. *The International Journal Of Cardiovascular Imaging* 2018, 34:1725-1730.
259. Burroughs Peña MS, Swett K, Kaplan RC, Perreira K, Daviglius M, Kansal MM, Cai J, Giachello AL, Gellman MD, **Velazquez EJ**, Rodriguez CJ. Childhood and adult exposure to secondhand tobacco smoke and cardiac structure and function: results from Echo-SOL. *Open Heart* 2018, 5:e000831.
260. Siddiqui I, Rajagopal S, Brucker A, Chiswell K, Christopher B, Alenezi F, Mandawat A, Rivera D, Arges K, Tapsos V, Kisslo J, **Velazquez E**, Douglas PS, Samad Z. Clinical and Echocardiographic Predictors of Outcomes in Patients With Pulmonary Hypertension. *The American Journal Of Cardiology* 2018, 122:872-878.
261. Pellikka PA, She L, Holly TA, Lin G, Varadarajan P, Pai RG, Bonow RO, Pohost GM, Panza JA, Berman DS, Prior DL, Asch FM, Borges-Neto S, Grayburn P, Al-Khalidi HR, Miszalski-Jamka K, Desvigne-Nickens P, Lee KL, **Velazquez EJ**, Oh JK. Variability in Ejection Fraction Measured By Echocardiography, Gated Single-Photon Emission Computed Tomography, and Cardiac Magnetic Resonance in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. *JAMA Network Open* 2018, 1:e181456.
262. Bouabdallaoui N, Stevens SR, Doenst T, Petrie MC, Al-Attar N, Ali IS, Ambrosy AP, Barton AK, Cartier R, Cherniavsky A, Demondion P, Desvigne-Nickens P, Favaloro RR, Gradinac S, Heinisch P, Jain A, Jasinski M, Jouan J, Kalil RAK, Menicanti L, Michler RE, Rao V, Smith PK, Zembala M, **Velazquez EJ**, Al-Khalidi HR, Rouleau JL. Society of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization. *Circulation. Heart Failure* 2018, 11:e005531.

263. Alenezi F, Mandawat A, Il'Giovine ZJ, Shaw LK, Siddiqui I, Tapson VF, Arges K, Rivera D, Romano MMD, **Velazquez EJ**, Douglas PS, Samad Z, Rajagopal S. Clinical Utility and Prognostic Value of Right Atrial Function in Pulmonary Hypertension. *Circulation. Cardiovascular Imaging* 2018, 11:e006984.
264. **Velazquez EJ**, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E. Angiotensin-Nepriylsin Inhibition in Acute Decompensated Heart Failure. *The New England Journal Of Medicine* 2019, 380:539-548.
265. Hunter WG, McGarrah RW, Kelly JP, Khouri MG, Craig DM, Haynes C, Felker GM, Hernandez AF, **Velazquez EJ**, Kraus WE, Shah SH. High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. *Journal Of The American College Of Cardiology* 2019, 73:177-186.
266. Alenezi F, Fudim M, Rymer J, Dunning A, Chiswell K, Swaminathan M, Bottiger B, Velagapudi P, Nicoara A, Kisslo J, **Velazquez E**, Vemulapalli S, Bloomfield GS, Samad Z. Predictors and Changes in Cardiac Hemodynamics and Geometry With Transcatheter Aortic Valve Implantation. *The American Journal Of Cardiology* 2019, 123:813-819.
267. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, **Velazquez EJ**. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. *Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography* 2019, 32:1-64.
268. Alenezi F, Ambrosy AP, Phelan M, Chiswell K, Abudaqa L, Alajmi H, Kisslo J, **Velazquez EJ**. Left Ventricular Global Longitudinal Strain Can Reliably Be Measured from a Single Apical Four-Chamber View in Patients with Heart Failure. *Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography* 2019, 32:317-318.
269. Bishawi M, Zanotti G, Shaw L, MacKenzie M, Castleberry A, Bartels K, Schroder J, **Velazquez E**, Swaminathan M, Rogers J, Milano C. Tricuspid Valve Regurgitation Immediately After Heart Transplant and Long-Term Outcomes. *The Annals Of Thoracic Surgery* 2019, 107:1348-1355.
270. Bloomfield GS, Kirwa K, Agarwal A, Eliot MN, Alenezi F, Carter EJ, Foster MC, Kimaiyo S, Lumsden R, Menya D, Mitter SS, **Velazquez EJ**, Vedanthan R, Wellenius GA. Effects of a Cookstove Intervention on Cardiac Structure, Cardiac Function, and Blood Pressure in Western Kenya. *Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography* 2019, 32:427-430.
271. Ambrosy AP, Stevens SR, Al-Khalidi HR, Rouleau JL, Bouabdallaoui N, Carson PE, Adlbrecht C, Cleland JGF, Dabrowski R, Golba KS, Pina IL, Sueta CA, Roy A, Sopko G, Bonow RO, **Velazquez EJ**. Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. *European Journal Of Heart Failure* 2019, 21:373-381.
272. Eisenstein EL, Prather K, Greene SJ, Harding T, Harrington A, Gabriel D, Jones I, Mentz RJ, **Velazquez EJ**, Anstrom KJ. Death: The Simple Clinical Trial Endpoint. *Studies In Health Technology And Informatics* 2019, 257:86-91.
273. Kelly JP, Andonian BJ, Patel MJ, Huang Z, Shaw LK, McGarrah RW, Borges-Neto S, **Velazquez EJ**, Kraus WE. Trends in cardiorespiratory fitness: The evolution of exercise treadmill testing at a single Academic Medical Center from 1970 to 2012. *American Heart Journal* 2019, 210:88-97.
274. Doenst T, Haverich A, Serruys P, Bonow RO, Kappetein P, Falk V, **Velazquez E**, Diegeler A, Sigusch H. PCI and CABG for Treating Stable Coronary Artery Disease: JACC Review Topic of the Week. *Journal Of The American College Of Cardiology* 2019, 73:964-976.

275. Nicolau JC, Stevens SR, Al-Khalidi HR, Jatene FB, Furtado RHM, Dallan LAO, Lisboa LAF, Desvigne-Nickens P, Haddad H, Jolicoeur EM, Petrie MC, Doenst T, Michler RE, Ohman EM, Maddury J, Ali I, Deja MA, Rouleau JL, **Velazquez EJ**, Hill JA. Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. *International Journal Of Cardiology* 2019, 291:36-41.
276. Morrow DA, **Velazquez EJ**, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. *Circulation* 2019, 139:2285-2288.
277. Morrow DA, **Velazquez EJ**, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, Rocha R, Braunwald E. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. *European Heart Journal* 2019, 40:3345-3352.
278. Rao VS, Ahmad T, Brisco-Bacik MA, Bonventre JV, Wilson FP, Siew ED, Felker GM, Anstrom KK, Mahoney DD, Bart BA, Tang WHW, **Velazquez EJ**, Testani JM. Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. *Circulation. Heart Failure* 2019, 12:e005552.
279. Ambrosy AP, DeVore AD, **Velazquez EJ**. In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. *European Journal Of Heart Failure* 2019, 21:1008-1011.
280. Alenezi F, Bloomfield GS, Okeke NL, Velagapudi P, Abudaqa L, Ijioma N, Dunning A, Alajmi H, Clement ME, Shah SH, Naggie S, **Velazquez EJ**. Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus. *The American Journal Of Cardiology* 2019, 124:966-971.
281. Shelburne NJ, Parikh KS, Chiswell K, Shaw LK, Sivak J, Arges K, Tomfohr J, **Velazquez EJ**, Kisslo J, Samad Z, Rajagopal S. Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension. *The American Journal Of Cardiology* 2019, 124:1298-1304.
282. Howlett JG, Stebbins A, Petrie MC, Jhund PS, Castelvechchio S, Cherniavsky A, Sueta CA, Roy A, Piña IL, Wurm R, Drazner MH, Andersson B, Battle C, Senni M, Chrzanowski L, Merkely B, Carson P, Desvigne-Nickens PM, Lee KL, **Velazquez EJ**, Al-Khalidi HR. CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial. *JACC. Heart Failure* 2019, 7:878-887.
283. Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, Pohost GM, Sopko G, Chrzanowski L, Mark DB, Kukulski T, Favalaro LE, Maurer G, Farsky PS, Tan RS, Asch FM, **Velazquez EJ**, Rouleau JL, Lee KL, Bonow RO. Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. *The New England Journal Of Medicine* 2019, 381:739-748.
284. Vedanthan R, Kamano JH, DeLong AK, Naanyu V, Binanay CA, Bloomfield GS, Chrysanthopoulou SA, Finkelstein EA, Hogan JW, Horowitz CR, Inui TS, Menya D, Orango V, **Velazquez EJ**, Were MC, Kimaiyo S, Fuster V. Community Health Workers Improve Linkage to Hypertension Care in Western Kenya. *Journal Of The American College Of Cardiology* 2019, 74:1897-1906.
285. DeVore AD, Yow E, Krucoff MW, Sherwood MW, Shaw LK, Chiswell K, O'Connor CM, Ohman EM, **Velazquez EJ**. Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction. *ESC Heart Failure* 2019, 6:1233-1242.

286. Panza JA, **Velazquez EJ**, Bonow RO. Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. Reply. *The New England Journal Of Medicine* 2019, 381:2374.
287. Tsang MYC, She L, Miller FA, Choi JO, Michler RE, Grayburn PA, Bonow RO, Menicanti L, Deja MA, Castelvich S, Rao V, Smith PK, Kukulski T, Sopko G, Prior DL, **Velazquez EJ**, Lee KL, Oh JK. Differential Impact of Mitral Valve Repair on Outcome of Coronary Artery Bypass Grafting With or Without Surgical Ventricular Reconstruction in the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. *Structural Heart : The Journal Of The Heart Team* 2019, 3:302-308.
288. Krishnamoorthy V, Chaikittisilpa N, Lee J, Mackensen GB, Gibbons EF, Laskowitz D, Hernandez A, **Velazquez E**, Lele AV, Vavilala MS. Speckle Tracking Analysis of Left Ventricular Systolic Function Following Traumatic Brain Injury: A Pilot Prospective Observational Cohort Study. *Journal Of Neurosurgical Anesthesiology* 2020, 32:156-161.
289. Butler J, Greene SJ, Shah SH, Shah SJ, Anstrom KJ, Kim RJ, Kalogeropoulos AP, **Velazquez EJ**, Hernandez AF, Desvigne-Nickens P, Scherzer R, Hsue PY, Braunwald E. Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. *Journal Of Cardiac Failure* 2020, 26:371-380.
290. DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, **Velazquez EJ**. Initiation of Angiotensin-Nepriylsin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. *JAMA Cardiology* 2020, 5:202-207.
291. Barac YD, Nicoara A, Bishawi M, Schroder JN, Daneshmand MA, Hashmi NK, **Velazquez E**, Rogers JG, Patel CB, Milano CA. Durability and Efficacy of Tricuspid Valve Repair in Patients Undergoing Left Ventricular Assist Device Implantation. *JACC. Heart Failure* 2020, 8:141-150.
292. Patel RB, Alenezi F, Sun JL, Alhanti B, Vaduganathan M, Oh JK, Redfield MM, Butler J, Hernandez AF, **Velazquez EJ**, Shah SJ. Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. *Journal Of Cardiac Failure* 2020, 26:270-275.
293. Patel PA, Ambrosy AP, Phelan M, Alenezi F, Chiswell K, Van Dyke MK, Tomfohr J, Honarpour N, **Velazquez EJ**. Association between systolic ejection time and outcomes in heart failure by ejection fraction. *European Journal Of Heart Failure* 2020, 22:1174-1182.
294. Daubert MA, Sivak J, Dunning A, Douglas PS, Coyne B, Wang TY, Mark DB, **Velazquez EJ**. Implications of Abnormal Exercise Electrocardiography With Normal Stress Echocardiography. *JAMA Internal Medicine* 2020, 180:494-502.
295. Muiruri C, Longenecker CT, Meissner EG, Okeke NL, Pettit AC, Thomas K, **Velazquez E**, Bloomfield GS. Prevention of cardiovascular disease for historically marginalized racial and ethnic groups living with HIV: A narrative review of the literature. *Progress In Cardiovascular Diseases* 2020, 63:142-148.
296. **Velazquez EJ**. Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting to Treat Ischemic Cardiomyopathy? *JAMA Cardiology* 2020, 5:641-642.
297. Daubert MA, White JA, Al-Khalidi HR, **Velazquez EJ**, Rao SV, Crowley AL, Zeymer U, Kasprzak JD, Guetta V, Krucoff MW, Douglas PS. Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era. *American Heart Journal* 2020, 223:87-97.
298. O'Connor KD, Brophy T, Fonarow GC, Blankstein R, Swaminathan RV, Xu H, Matsouaka RA, Albert NM, **Velazquez EJ**, Yancy CW, Heidenreich PA, Hernandez AF, DeVore AD. Testing for Coronary

- Artery Disease in Older Patients With New-Onset Heart Failure: Findings From Get With The Guidelines-Heart Failure. *Circulation. Heart Failure* 2020, 13:e006963.
299. Fudim M, Sayeed S, Xu H, Matsouaka RA, Heidenreich PA, **Velazquez EJ**, Yancy CW, Fonarow GC, Hernandez AF, DeVore AD. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. *Circulation. Heart Failure* 2020, 13:e006645.
300. Redouane B, Greene SJ, Fudim M, Vaduganathan M, Ambrosy AP, Sun JL, DeVore AD, McNulty SE, Mentz RJ, Hernandez AF, Felker GM, Cooper LB, Borlaug BA, **Velazquez EJ**, Margulies KB, Sharma A. Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. *Circulation. Heart Failure* 2020, 13:e006758.
301. Doenst T, Haddad H, Stebbins A, Hill JA, **Velazquez EJ**, Lee KL, Rouleau JL, Sopko G, Farsky PS, Al-Khalidi HR. Renal function and coronary bypass surgery in patients with ischemic heart failure. *The Journal Of Thoracic And Cardiovascular Surgery* 2020.
302. Kim KH, She L, Lee KL, Dabrowski R, Grayburn PA, Rajda M, Prior DL, Desvigne-Nickens P, Zoghbi WA, Senni M, Stefanelli G, Beghi C, Huynh T, **Velazquez EJ**, Oh JK, Lin G. Incremental prognostic value of echocardiography of left ventricular remodeling and diastolic function in STICH trial. *Cardiovascular Ultrasound* 2020, 18:17.
303. Mullan C, Caraballo C, Ravindra NG, Miller PE, McCullough M, Brown K, Aw TW, Gruen J, Clarke JD, **Velazquez EJ**, Geirsson A, Mori M, Desai NR, Ahmad T. Psychiatric Comorbidity and Outcomes After Left Ventricular Assist Device Implantation for End-Stage Heart Failure. *JACC. Heart Failure* 2020, 8:569-577.
304. Mullan C, Caraballo C, Ravindra NG, Miller PE, Mori M, McCullough M, Clarke JD, Anwer M, **Velazquez EJ**, Geirsson A, Desai NR, Ahmad T. Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation. *The Journal Of Heart And Lung Transplantation : The Official Publication Of The International Society For Heart Transplantation* 2020, 39:926-933.
305. Gruen J, Caraballo C, Miller PE, McCullough M, Mezzacappa C, Ravindra N, Mullan CW, Reinhardt SW, Mori M, **Velazquez E**, Geirsson A, Ahmad T, Desai NR. Sex Differences in Patients Receiving Left Ventricular Assist Devices for End-Stage Heart Failure. *JACC. Heart Failure* 2020, 8:770-779.
306. Daubert MA, **Velazquez EJ**, Wang TY. Implications of ST Changes During Normal Echocardiography-Reply. *JAMA Internal Medicine* 2020, 180:1257-1258.
307. McPadden J, Warner F, Young HP, Hurley NC, Pulk RA, Singh A, Durant TJ, Gong G, Desai N, Haimovich A, Taylor RA, Gunel M, Dela Cruz CS, Farhadian SF, Siner J, Villanueva M, Churchwell K, Hsiao A, Torre CJ, **Velazquez EJ**, Herbst RS, Iwasaki A, Ko AI, Mortazavi BJ, Krumholz HM, Schulz WL. Clinical Characteristics and Outcomes for 7,995 Patients with SARS-CoV-2 Infection. *MedRxiv : The Preprint Server For Health Sciences* 2020.
308. Gaziano TA, Fonarow GC, **Velazquez EJ**, Morrow DA, Braunwald E, Solomon SD. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. *JAMA Cardiology* 2020, 5:1236-1244.
309. Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Duffy CI, Gurmu Y, **Velazquez EJ**, Morrow DA. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. *JACC. Heart Failure* 2020, 8:834-843.

310. Ambrosy AP, Braunwald E, Morrow DA, DeVore AD, McCague K, Meng X, Duffy CI, Rocha R, **Velazquez EJ**. Angiotensin Receptor-Nepriylsin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. *Journal Of The American College Of Cardiology* 2020, 76:1034-1048.
311. Hennessey KC, Shah N, Soufer A, Wang Y, Agarwal V, McNamara RL, Crandall I, Balan S, Pereira J, Kim Y, Hur DJ, **Velazquez EJ**, Sugeng L, Faridi KF. Inpatient Transthoracic Echocardiography during the COVID-19 Pandemic: Evaluating a New Triage Process. *Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography* 2020, 33:1418-1419.
312. Berardi C, Braunwald E, Morrow DA, Mulder HS, Duffy CI, O'Brien TX, Ambrosy AP, Chakraborty H, **Velazquez EJ**, DeVore AD. Angiotensin-Nepriylsin Inhibition in Black Americans: Data From the PIONEER-HF Trial. *JACC. Heart Failure* 2020, 8:859-866.
313. Faridi KF, Hennessey KC, Shah N, Soufer A, Wang Y, Sugeng L, Agarwal V, Sharma R, Sewanan LR, Hur DJ, **Velazquez EJ**, McNamara RL. Left Ventricular Systolic Function and Inpatient Mortality in Patients Hospitalized with Coronavirus Disease 2019 (COVID-19). *Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography* 2020, 33:1414-1415.
314. Caraballo C, McCullough M, Fuery MA, Chouairi F, Keating C, Ravindra NG, Miller PE, Malinis M, Kashyap N, Hsiao A, Wilson FP, Curtis JP, Grant M, **Velazquez EJ**, Desai NR, Ahmad T. COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system. *PloS One* 2020, 15:e0238829.
315. Clark KAA, **Velazquez EJ**. Heart Failure With Preserved Ejection Fraction: Time for a Reset. *JAMA* 2020, 324:1506-1508.
316. **Velazquez EJ**, Reinhardt SW. Limitations of Natriuretic Peptide Levels in Establishing SGLT-2 Inhibitors for Heart Failure Care. *Journal Of The American College Of Cardiology* 2020, 76:2086-2088.
317. Lansky A, Shah T, Wijns W, Stefanini GG, Farb A, Kaplan A, Xu B, Pietras C, **Velazquez E**, Serruys PW, Mahfoud F, Baumbach A. Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2020, 16:787-793.
318. Romano MMD, Moreira HT, Marin-Neto JA, Baccelli PE, Alenezi F, Klem I, Maciel BC, Kisslo J, Schmidt A, **Velazquez EJ**. Early impairment of myocardial deformation assessed by regional speckle-tracking echocardiography in the indeterminate form of Chagas disease without fibrosis detected by cardiac magnetic resonance. *PLoS Neglected Tropical Diseases* 2020, 14:e0008795.
319. Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, **Velazquez E**, Weber MA, Jamerson KA. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. *American Journal Of Hypertension* 2021, 34:531-539.
320. Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, **Velazquez EJ**, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. *JACC. Heart Failure* 2021, 9:115-123.

321. Miller PE, Chouairi F, Thomas A, Kunitomo Y, Aslam F, Canavan ME, Murphy C, Daggula K, Metkus T, Vallabhajosyula S, Carnicelli A, Katz JN, Desai NR, Ahmad T, **Velazquez EJ**, Brennan J. Transition From an Open to Closed Staffing Model in the Cardiac Intensive Care Unit Improves Clinical Outcomes. *Journal Of The American Heart Association* 2021, 10:e018182.
322. Doenst T, **Velazquez EJ**, Michler RE. Restoring ventricular restoration: A call to re-evaluate a surgical therapy considered ineffective. *Journal Of Cardiac Surgery* 2021, 36:693-695.
323. Pareek M, Singh A, Vadlamani L, Eder M, Pacor J, Park J, Ghazizadeh Z, Heard A, Cruz-Solbes AS, Nikooie R, Gier C, Ahmed ZV, Freeman JV, Meadows J, Smolderen KGE, Lampert R, **Velazquez EJ**, Ahmad T, Desai NR. Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). *The American Journal Of Cardiology* 2021, 146:99-106.
324. Berg DD, Samsky MD, **Velazquez EJ**, Duffy CI, Gurmu Y, Braunwald E, Morrow DA, DeVore AD. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. *Circulation. Heart Failure* 2021, 14:e007034.
325. Farsky PS, White J, Al-Khalidi HR, Sueta CA, Rouleau JL, Panza JA, **Velazquez EJ**, O'Connor CM. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. *The Journal Of Thoracic And Cardiovascular Surgery* 2021.
326. McPadden J, Warner F, Young HP, Hurley NC, Pulk RA, Singh A, Durant TJS, Gong G, Desai N, Haimovich A, Taylor RA, Gunel M, Dela Cruz CS, Farhadian SF, Siner J, Villanueva M, Churchwell K, Hsiao A, Torre CJ, **Velazquez EJ**, Herbst RS, Iwasaki A, Ko AI, Mortazavi BJ, Krumholz HM, Schulz WL. Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection. *PloS One* 2021, 16:e0243291.
327. Greene SJ, **Velazquez EJ**, Anstrom KJ, Eisenstein EL, Sapp S, Morgan S, Harding T, Sachdev V, Ketema F, Kim DY, Desvigne-Nickens P, Pitt B, Mentz RJ. Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial. *JACC. Heart Failure* 2021, 9:325-335.
328. Oikonomou EK, Van Dijk D, Parise H, Suchard MA, de Lemos J, Antoniades C, **Velazquez EJ**, Miller EJ, Khera R. A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST). *European Heart Journal* 2021, 42:2536-2548.
329. Ahmad T, Yamamoto Y, Biswas A, Ghazi L, Martin M, Simonov M, Hsiao A, Kashyap N, **Velazquez EJ**, Desai NR, Wilson FP. REVeAL-HF: Design and Rationale of a Pragmatic Randomized Controlled Trial Embedded Within Routine Clinical Practice. *JACC. Heart Failure* 2021, 9:409-419.
330. Guha A, Caraballo C, Jain P, Miller PE, Owusu-Guha J, Clark KAA, **Velazquez EJ**, Ahmad T, Baldassarre LA, Addison D, Weintraub NL, Desai NR. Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantation. *ESC Heart Failure* 2021.
331. Sharma A, Greene S, Vaduganathan M, Fudim M, Ambrosy AP, Sun JL, McNulty SE, Hernandez AF, Borlaug BA, **Velazquez EJ**, Mentz RJ, DeVore AD, Alhanti B, Margulies K, Felker GM. Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. *ESC Heart Failure* 2021.
332. Park J, Kim Y, Pereira J, Hennessey KC, Faridi KF, McNamara RL, **Velazquez EJ**, Hur DJ, Sugeng L, Agarwal V. Understanding the role of left and right ventricular strain assessment in patients hospitalized with COVID-19. *American Heart Journal Plus : Cardiology Research And Practice* 2021, 6:100018.

333. Chouairi F, Fuery MA, Mullan CW, Caraballo C, Sen S, Maulion C, Wilkinson ST, Surti T, McCullough M, Miller PE, Pacor J, Leifer ES, Felker GM, **Velazquez EJ**, Fiuzat M, O'Connor CM, Januzzi JL, Desai NR, Ahmad T. The Impact of Depression on Outcomes in Patients with Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. *Journal Of Cardiac Failure* 2021.